Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Andrew Schally

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Disorders

Prostatic Neoplasms

Procedures

Radioimmunoassay

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
143
Halmos, Gabor
116
Groot, Kate
76
Szepeshazi, Karoly
74
Nagy, Attila
63
Varga, Jozsef
45
Pinski, Jacek
41
Armatis, Patricia
37
Cai, Renzhi
32
Zarandi, Marta
24
Kiaris, Hippokratis
23
Plonowski, Artur
22
Engel, Jörg
20
Radulovic, Sinisa
18
Kovacs, Magdolna
15
Keller, Gunhild

Sign-in to see all Coauthors

Publications

TOP 3
Rózsa Bernadett; Juhász Aliz; Treszl Andrea; Tóth György; Flaskó Tibor; Dezsö Balázs; Block Norman L; Schally Andrew V; Halmos Gábor
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
Laklai Hanane; Laval Séverine; Dumartin Laurent; Rochaix Philippe; Hagedorn Martin; Bikfalvi Andreas; Le Guellec Sophie; Delisle Marie-Bernadette; Schally Andrew V; Susini Christiane; Pyronnet Stéphane; Bousquet Corinne
Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.
Hohla Florian; Buchholz Stefan; Schally Andrew V; Seitz Stefan; Rick Ferenc G; Szalontay Luca; Varga Jozsef L; Zarandi Marta; Halmos Gabor; Vidaurre Irving; Krishan Awtar; Kurtoglu Metin; Chandna Sudhir; Aigner Elmar; Datz Christian
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Andrew Schally (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Rózsa Bernadett; Juhász Aliz; Treszl Andrea; Tóth György; Flaskó Tibor; Dezsö Balázs; Block Norman L; Schally Andrew V; Halmos Gábor
Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
International journal of oncology 2009;35(5):1053-9.
2009: Laklai Hanane; Laval Séverine; Dumartin Laurent; Rochaix Philippe; Hagedorn Martin; Bikfalvi Andreas; Le Guellec Sophie; Delisle Marie-Bernadette; Schally Andrew V; Susini Christiane; Pyronnet Stéphane; Bousquet Corinne
Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(42):17769-74.
2009: Hohla Florian; Buchholz Stefan; Schally Andrew V; Seitz Stefan; Rick Ferenc G; Szalontay Luca; Varga Jozsef L; Zarandi Marta; Halmos Gabor; Vidaurre Irving; Krishan Awtar; Kurtoglu Metin; Chandna Sudhir; Aigner Elmar; Datz Christian
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Cell cycle (Georgetown, Tex.) 2009;8(19):3149-56.
2009: Buchholz Stefan; Seitz Stephan; Schally Andrew V; Engel Jörg B; Rick Ferenc G; Szalontay Luca; Hohla Florian; Krishan Awtar; Papadia Andrea; Gaiser Timo; Brockhoff Gero; Ortmann Olaf; Diedrich Klaus; Köster Frank
Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition.
International journal of oncology 2009;35(4):789-96.
2009: Treszl Andrea; Schally Andrew V; Seitz Stephan; Szalontay Luca; Rick Ferenc G; Szepeshazi Karoly; Halmos Gabor
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
Peptides 2009;30(9):1643-50.
2009: Seitz Stephan; Schally Andrew V; Treszl Andrea; Papadia Andrea; Rick Ferenc; Szalontay Luca; Szepeshazi Karoly; Ortmann Olaf; Halmos Gabor; Hohla Florian; Buchholz Stefan
Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
Anti-cancer drugs 2009;20(7):553-8.
2009: Theophanous Elena; Petraki Constantina; Scorilas Andreas; Komborozos Vassilios; Veloudis George; Varga Jozsef L; Zarandi Marta; Schally Andrew V; Koutsilieris Michael
The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer.
Molecular medicine (Cambridge, Mass.) 2009;15(7-8):242-7.
2009: Fu Li; Osuga Yutaka; Yano Tetsu; Takemura Yuri; Morimoto Chieko; Hirota Yasushi; Schally Andrew V; Taketani Yuji
Expression and possible implication of growth hormone-releasing hormone receptor splice variant 1 in endometriosis.
Fertility and sterility 2009;92(1):47-53.
2009: Köster Frank; Engel Jörg B; Schally Andrew V; Hönig Arnd; Schröer Andreas; Seitz Stephan; Hohla Florian; Ortmann Olaf; Diedrich Klaus; Buchholz Stefan
Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
Breast cancer research and treatment 2009;116(2):273-9.
2009: Telegdy Gyula; Tanaka Masaru; Schally Andrew V
Effects of the LHRH antagonist Cetrorelix on the brain function in mice.
Neuropeptides 2009;43(3):229-34.
2009: Valdehita Ana; Bajo Ana M; Schally Andrew V; Varga Jozsef L; Carmena María J; Prieto Juan C
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Molecular and cellular endocrinology 2009;302(1):41-8.
2009: Emons Günter; Sindermann Herbert; Engel Jürgen; Schally Andrew V; Gründker Carsten
Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
Neuroendocrinology 2009;90(1):15-8.
2008: Casanueva Felipe F; Camiña Jesus P; Carreira Marcos C; Pazos Yolanda; Varga Jozsef L; Schally Andrew V
Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(51):20452-7.
2008: Barabutis Nektarios; Schally Andrew V
Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(51):20470-5.
2008: Heinrich Elmar; Schally Andrew V; Buchholz Stefan; Rick Ferenc G; Halmos Gabor; Mile Melinda; Groot Kate; Hohla Florian; Zarandi Marta; Varga Jozsef L
Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
The Prostate 2008;68(16):1763-72.
2008: Seitz Stephan; Hohla Florian; Schally Andrew V; Moder Angelika; Engel Joerg B; Horn Felicitas; Varga Josef; Zarandi Marta; Ortmann Olaf; Köster Frank; Buchholz Stefan
Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Oncology reports 2008;20(5):1289-94.
2008: Volakaki Aspasia-Athina; Lafkas Daniel; Kassi Eva; Schally Andrew V; Papavassiliou Athanasios G; Kiaris Hippokratis
Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132.
Journal of molecular endocrinology 2008;41(5):389-92.
2008: Lee Lung-Ta; Schally Andrew V; Liebow Charles; Lee Ping-Ping; Lee Po-Huang; Lee Ming-Ting
Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
Anticancer research 2008;28(5A):2599-605.
2008: Hohla Florian; Moder Angelika; Mayrhauser Ursula; Hauser-Kronberger Cornelia; Schally Andrew V; Varga Jozsef L; Zarandi Marta; Buchholz Stefan; Huber Rudolf; Aigner Elmar; Ritter Markus; Datz Christian
Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon.
International journal of oncology 2008;33(1):137-43.
2008: Barabutis N; Schally A V
Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines.
British journal of cancer 2008;98(11):1790-6.
2008: Schally A V
New approaches to the therapy of various tumors based on peptide analogues.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(5):315-22.
2008: Bornstein S R; Wirth M P; Schally A V
Update on endocrine-related tumors.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2008;40(5):299-301.
2008: Stangelberger Anton; Schally Andrew V; Djavan Bob
New treatment approaches for prostate cancer based on peptide analogues.
European urology 2008;53(5):890-900.
2008: Szepeshazi Karoly; Schally Andrew V; Treszl Andrea; Seitz Stephan; Halmos Gabor
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Anti-cancer drugs 2008;19(4):349-58.
2008: Chatzistamou Ioulia; Volakaki Aspasia-Athina; Schally Andrew V; Kiaris Hippokratis; Kittas Christos
Expression of growth hormone-releasing hormone receptor splice variant 1 in primary human melanomas.
Regulatory peptides 2008;147(1-3):33-6.
2008: Zhao Lin; Yano Tetsu; Osuga Yutaka; Nakagawa Shunsuke; Oishi Hajime; Wada-Hiraike Osamu; Tang Xiaohui; Yano Naomi; Kugu Koji; Schally Andrew V; Taketani Yuji
Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
International journal of oncology 2008;32(3):593-601.
2008: Kidd Mark; Schally Andrew V; Pfragner Roswitha; Malfertheiner Maximillian V; Modlin Irvin M
Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Cancer 2008;112(6):1404-14.
2008: Schally Andrew V; Varga Jozsef L; Engel Jörg B
Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
Nature clinical practice. Endocrinology & metabolism 2008;4(1):33-43.
2008: Kovács Magdolna; Schally Andrew V; Varga József L; Zarándi Márta
Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists.
Current medicinal chemistry 2008;15(4):314-21.
2007: Hohla Florian; Schally Andrew V; Kanashiro Celia A; Buchholz Stefan; Baker Benjamin; Kannadka Chandrika; Moder Angelika; Aigner Elmar; Datz Christian; Halmos Gabor
Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(47):18671-6.
2007: Sotomayor Sandra; Carmena María J; Schally Andrew V; Varga Jozsef L; Sánchez-Chapado Manuel; Prieto Juan C; Bajo Ana M
Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
International journal of oncology 2007;31(5):1223-30.
2007: Engel Jörg B; Schally Andrew V; Dietl Johannes; Rieger Lorenz; Hönig Arnd
Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.
Molecular pharmaceutics 2007;4(5):652-8.
2007: Stangelberger Anton; Schally Andrew V; Zarandi Marta; Heinrich Elmar; Groot Kate; Havt Alexandre; Kanashiro Celia A; Varga Jozsef L; Halmos Gabor
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
The Prostate 2007;67(12):1339-53.
2007: Schally Andrew V
Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.
BJU international 2007;100 Suppl 2():2-4.
2007: Szepeshazi Karoly; Schally Andrew V; Halmos Gabor
LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
International journal of oncology 2007;30(6):1485-92.
2007: Kanashiro Celia A; Schally Andrew V; Zarandi Marta; Hammann Brian D; Varga Jozsef L
Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
International journal of oncology 2007;30(4):1019-28.
2007: Barabutis Nektarios; Tsellou Erasmia; Schally Andrew V; Kouloheri Stavroula; Kalofoutis Anastasios; Kiaris Hippokratis
Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(13):5575-9.
2007: Buchholz Stefan; Schally Andrew V; Engel Jörg B; Hohla Florian; Heinrich Elmar; Koester Frank; Varga Jozsef L; Halmos Gabor
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(6):1943-6.
2007: Engel Jörg B; Schally Andrew V
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
Nature clinical practice. Endocrinology & metabolism 2007;3(2):157-67.
2006: Hohla Florian; Schally Andrew V; Szepeshazi Karoly; Varga Jozsef L; Buchholz Stefan; Köster Frank; Heinrich Elmar; Halmos Gabor; Rick Ferenc G; Kannadka Chandrika; Datz Christian; Kanashiro Celia A
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(39):14513-8.
2006: Christodoulou C; Schally A V; Chatzistamou I; Kondi-Pafiti A; Lamnissou K; Kouloheri S; Kalofoutis A; Kiaris H
Expression of growth hormone-releasing hormone (GHRH) and splice variant of GHRH receptors in normal mouse tissues.
Regulatory peptides 2006;136(1-3):105-8.
2006: Halmos Gabor; Schally Andrew V; Bernardino Andrea L F; Varga Jozsef L
Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.
International journal of oncology 2006;29(2):463-9.
2006: Schally Andrew V; González Bárcena David
[History of clinical studies on hypothalamic hormone analogs in Mexico]
Gaceta médica de México 2006;142(4):315-25.
2006: Buchholz Stefan; Keller Gunhild; Schally Andrew V; Halmos Gabor; Hohla Florian; Heinrich Elmar; Koester Frank; Baker Benjamin; Engel Jörg B
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(27):10403-7.
2006: Kahán Zsuzsanna; Gardi János; Nyári Tibor; Földesi Imre; Hajnal-Papp Rozália; Ormándi Katalin; Lázár György; Thurzó László; Schally Andrew V
Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
International journal of oncology 2006;29(1):193-200.
2006: Keller Gunhild; Schally Andrew V; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
International journal of oncology 2006;28(6):1507-13.
2006: Zarandi Marta; Varga Jozsef L; Schally Andrew V; Horvath Judit E; Toller Gabor L; Kovacs Magdolna; Letsch Markus; Groot Kate; Armatis Patricia; Halmos Gabor
Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4610-5.
2006: Schally Andrew V; Varga Jozsef L
Antagonists of growth hormone-releasing hormone in oncology.
Combinatorial chemistry & high throughput screening 2006;9(3):163-70.
2006: Stangelberger Anton; Schally Andrew V; Nagy Attila; Szepeshazi Karoly; Kanashiro Celia A; Halmos Gabor
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
The Prostate 2006;66(2):200-10.
2006: Stangelberger Anton; Schally Andrew V; Letsch Markus; Szepeshazi Karoly; Nagy Attila; Halmos Gabor; Kanashiro Celia A; Corey Eva; Vessella Robert
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
International journal of cancer. Journal international du cancer 2006;118(1):222-9.
2006: Gaiser T; Rüschoff J; Schally A V; Keller G; Engel J B
[Receptors for luteinizing hormone releasing hormone expressed on melanoma, renal cell carcinoma and non Hodgkin lymphoma can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues]
Verhandlungen der Deutschen Gesellschaft für Pathologie 2006;90():186-92.
2005: Engel Jörg B; Schally Andrew V; Halmos Gabor; Baker Benjamin; Nagy Attila; Keller Gunhild
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
Endocrine-related cancer 2005;12(4):999-1009.
2005: Havt Alexandre; Schally Andrew V; Halmos Gabor; Varga Jozsef L; Toller Gabor L; Horvath Judit E; Szepeshazi Karoly; Köster Frank; Kovitz Kevin; Groot Kate; Zarandi Marta; Kanashiro Celia A
The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(48):17424-9.
2005: Stangelberger Anton; Schally Andrew V; Varga Jozsef L; Zarandi Marta; Cai Ren-Zhi; Baker Benjamin; Hammann Brian D; Armatis Patricia; Kanashiro Celia A
Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.
European journal of cancer (Oxford, England : 1990) 2005;41(17):2735-44.
2005: Keller Gunhild; Schally Andrew V; Nagy Attila; Halmos Gabor; Baker Benjamin; Engel Jorg B
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
Cancer 2005;104(10):2266-74.
2005: Nagy Attila; Schally Andrew V
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Biology of reproduction 2005;73(5):851-9.
2005: Schally Andrew V
[The discovery of hypothalamic hormones and the development of antitumor analogs]
Annales d'urologie 2005;39 Suppl 3():S46-50.
2005: Szepeshazi Karoly; Schally Andrew V; Nagy Attila; Halmos Gabor
Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Pancreas 2005;31(3):275-82.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
European journal of cancer (Oxford, England : 1990) 2005;41(14):2196-202.
2005: Engel Jorg B; Schally Andrew V; Halmos Gabor; Baker Ben; Nagy Attila; Keller Gunhild
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
Cancer 2005;104(6):1312-21.
2005: Jaeger Laura B; Banks William A; Varga Jozsef L; Schally Andrew V
Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(35):12495-500.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Halmos Gabor; Engel Jörg B
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5549-57.
2005: Engel Jörg B; Schally Andrew V; Halmos Gabor; Baker Benjamin; Nagy Attila; Keller Gunhild
Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
European journal of cancer (Oxford, England : 1990) 2005;41(12):1824-30.
2005: Kanashiro Celia A; Schally Andrew V; Varga Jozsef L; Hammann Brian; Halmos Gabor; Zarandi Marta
Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
Cancer letters 2005;226(2):123-31.
2005: Stangelberger Anton; Schally Andrew V; Varga Jozsef L; Hammann Brian D; Groot Kate; Halmos Gabor; Cai Ren-Zhi; Zarandi Marta
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
The Prostate 2005;64(3):303-15.
2005: Keller Gunhild; Schally Andrew V; Groot Kate; Toller Gabor L; Havt Alexandre; Köster Frank; Armatis Patricia; Halmos Gabor; Zarandi Marta; Varga Jozsef L; Engel Jörg B
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(30):10628-33.
2005: Keller Gunhild; Schally Andrew V; Gaiser Timo; Nagy Attila; Baker Benjamin; Westphal Gabriela; Halmos Gabor; Engel Jörg B
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
Cancer research 2005;65(13):5857-63.
2005: Kanashiro Celia A; Schally Andrew V; Nagy Attila; Halmos Gabor
Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms.
International journal of oncology 2005;27(1):169-74.
2005: Heuser M; Schlott T; Schally A V; Kahler E; Schliephake R; Laabs S O; Hemmerlein B
Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion.
The Journal of urology 2005;173(6):2154-9.
2005: Collado Beatriz; Carmena María J; Sánchez-Chapado Manuel; Ruíz-Villaespesa Antonio; Bajo Ana M; Fernández-Martínez Ana B; Varga Jozsef L; Schally Andrew V; Prieto Juan C
Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
International journal of oncology 2005;26(6):1629-35.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Toller Gabor L; Groot Kate; Havt Alexandre; Armatis Patricia; Zarandi Marta; Varga Jozsef L; Halmos Gabor
Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
The Journal of clinical endocrinology and metabolism 2005;90(6):3614-21.
2005: Keller Gunhild; Engel Jörg B; Schally Andrew V; Nagy Attila; Hammann Brian; Halmos Gabor
Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
International journal of cancer. Journal international du cancer 2005;114(5):831-5.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Nagy Attila; Chism David D; Halmos Gabor
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Fertility and sterility 2005;83 Suppl 1():1125-33.
2005: Engel Jörg B; Keller Gunhild; Schally Andrew V; Halmos Gabor; Hammann Brian; Nagy Attila
Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2408-15.
2005: Rekasi Zoltan; Czompoly Tamas; Schally Andrew V; Boldizsar Ferenc; Varga Jozsef L; Zarandi Marta; Berki Timea; Horvath Reka A; Nemeth Peter
Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(9):3435-40.
2005: Alba Maria; Schally Andrew V; Salvatori Roberto
Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog.
Endocrinology 2005;146(3):1506-13.
2005: Lasfer Malika; Vadrot Nathalie; Schally Andrew V; Nagy Attila; Halmos Gabor; Pessayre Dominique; Feldmann Gérard; Reyl-Desmars Florence J
Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.
Journal of hepatology 2005;42(2):230-7.
2005: Kanashiro Celia A; Schally Andrew V; Cai R-Z; Halmos Gabor
Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
Anti-cancer drugs 2005;16(2):159-65.
2005: Comaru-Schally Ana Maria; Schally Andrew V
A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review).
International journal of oncology 2005;26(2):301-9.
2005: Chatzistamou Ioulia; Kondi-Pafiti Agatha; Politi Ekaterini; Koutselini Helen; Schally Andrew V
Detection of growth hormone-releasing hormone in cytologic specimens of primary breast carcinoma.
Acta cytologica 2005;49(1):108-9.
2005: Stangelberger Anton; Schally Andrew V; Varga Jozsef L; Zarandi Marta; Szepeshazi Karoly; Armatis Patricia; Halmos Gabor
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):49-57.
2005: Fintini Danilo; Alba Maria; Schally Andrew V; Bowers Cyril Y; Parlow A F; Salvatori Roberto
Effects of combined long-term treatment with a growth hormone-releasing hormone analogue and a growth hormone secretagogue in the growth hormone-releasing hormone knock out mouse.
Neuroendocrinology 2005;82(3-4):198-207.
2005: Nagy A; Schally A V
Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy.
Current pharmaceutical design 2005;11(9):1167-80.
2005: Schally Andrew V
[From the discovery of hypothalamic hormones to the development of analogues as anti-cancer agents]
La Revue du praticien 2005;Spec. No():20-4.
2005: Kiaris Hippokratis; Schally Andrew V; Kalofoutis Anastasios
Extrapituitary effects of the growth hormone-releasing hormone.
Vitamins and hormones 2005;70():1-24.
2004: Kanashiro Celia A; Schally Andrew V; Zarandi Marta; Hammann Brian D; Varga Jozsef L
Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
International journal of cancer. Journal international du cancer 2004;112(4):570-6.
2004: Günthert Andreas R; Gründker Carsten; Bongertz Till; Nagy Attila; Schally Andrew V; Emons Günter
Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system.
Breast cancer research and treatment 2004;87(3):255-64.
2004: Günthert Andreas R; Gründker Carsten; Bongertz Till; Schlott Thilo; Nagy Attila; Schally Andrew V; Emons Günter
Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
American journal of obstetrics and gynecology 2004;191(4):1164-72.
2004: Toller Gabor L; Horvath Judit E; Schally Andrew V; Halmos Gabor; Varga Jozsef L; Groot Kate; Chism David; Zarandi Marta
Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(42):15160-5.
2004: Chatzistamou Ioulia; Schally Andrew V; Kiaris Hippokratis; Politi Ekaterini; Varga Jozsef; Kanellis George; Kalofoutis Anastasios; Pafiti Agatha; Koutselini Helen
Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers.
European journal of endocrinology / European Federation of Endocrine Societies 2004;151(3):391-6.
2004: Schally Andrew V; Nagy Attila
Chemotherapy targeted to cancers through tumoral hormone receptors.
Trends in endocrinology and metabolism: TEM 2004;15(7):300-10.
2004: Schally A V; Szepeshazi K; Nagy A; Comaru-Schally A M; Halmos G
New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.
Cellular and molecular life sciences : CMLS 2004;61(9):1042-68.
2004: Horvath Judit E; Toller Gabor L; Schally Andrew V; Bajo Ana-Maria; Groot Kate
Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(14):4996-5001.
2004: Collado Beatriz; Carmena María J; Cortés Joaquín; Schally Andrew V; Prieto Juan C
Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Galphas and Galphai protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary.
International journal of oncology 2004;24(3):725-30.
2004: Varga Jozsef L; Schally Andrew V; Horvath Judit E; Kovacs Magdolna; Halmos Gabor; Groot Kate; Toller Gabor L; Rekasi Zoltan; Zarandi Marta
Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(6):1708-13.
2004: Letsch M; Schally A V; Stangelberger A; Groot K; Varga J L
Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
European journal of cancer (Oxford, England : 1990) 2004;40(3):436-44.
2004: Letsch Markus; Schally Andrew V; Szepeshazi Karoly; Halmos Gabor; Nagy Attilla
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
The Journal of urology 2004;171(2 Pt 1):911-5.
2004: Bajo A M; Schally A V; Groot K; Szepeshazi K
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.
British journal of cancer 2004;90(1):245-52.
2004: Schally Andrew V
[New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin]
Anales de la Real Academia Nacional de Medicina 2004;121(3):493-500.
2003: Kanashiro Celia A; Schally Andrew V; Groot Kate; Armatis Patricia; Bernardino Andrea L F; Varga Jozsef L
Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(26):15836-41.
2003: Szereday Zoltan; Schally Andrew V; Varga Jozsef L; Kanashiro Celia A; Hebert Francine; Armatis Patricia; Groot Kate; Szepeshazi Karoly; Halmos Gabor; Busto Rebeca
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
Cancer research 2003;63(22):7913-9.
2003: Letsch Markus; Schally Andrew V; Szepeshazi Karoly; Halmos Gabor; Nagy Attila
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4505-13.
2003: Szepeshazi Karoly; Schally Andrew V; Nagy Attila; Wagner Brady W; Bajo Ana Maria; Halmos Gabor
Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Cancer 2003;98(7):1401-10.
2003: Bajo Ana M; Schally Andrew V; Halmos Gabor; Nagy Attila
Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3742-8.
2003: Kiaris Hippokratis; Koutsilieris Michael; Kalofoutis Anastasios; Schally Andrew V
Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists.
Expert opinion on investigational drugs 2003;12(8):1385-94.
2003: Kiaris Hippokratis; Chatzistamou Ioulia; Schally Andrew V; Halmos Gabor; Varga Jozsef L; Koutselini Helen; Kalofoutis Anastasios
Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(16):9512-7.
2003: González-Barcena David; Schally Andrew V; Vadillo-Buenfil Manuel; Cortez-Morales Adolfo; Hernández L Victor; Cardenas-Cornejo Imelda; Comaru-Schally Ana Maria
Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
The Prostate 2003;56(3):183-91.
2003: Szereday Zoltan; Schally Andrew V; Szepeshazi Karoly; Bajo Ana-Maria; Hebert Francine; Halmos Gabor; Nagy Attila
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
International journal of oncology 2003;22(5):1141-6.
2003: Halmos Gabor; Schally Andrew V; Comaru-Schally Ana Maria; Nagy Attila; Irimpen Anand
Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.
Life sciences 2003;72(23):2669-74.
2003: Siejka A; Lawnicka H; Komorowski J; Schally A V; Stepien T; Krupinski R; Stepien H
GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells.
Life sciences 2003;72(22):2473-9.
2003: Schally Andrew V; Nagy Attila
New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin.
Life sciences 2003;72(21):2305-20.
2003: Letsch Markus; Schally Andrew V; Busto Rebeca; Bajo Ana M; Varga Jozsef L
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(3):1250-5.
2003: Garcia-Fernandez M Olga; Schally Andrew V; Varga Jozsef L; Groot Kate; Busto Rebeca
The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
Breast cancer research and treatment 2003;77(1):15-26.
2003: Guillermet Julie; Saint-Laurent Nathalie; Rochaix Philippe; Cuvillier Olivier; Levade Thierry; Schally Andrew V; Pradayrol Lucien; Buscail Louis; Susini Christiane; Bousquet Corinne
Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(1):155-60.
2002: Krebs Linda J; Wang Xiaopeng; Nagy Atilla; Schally Andrew V; Prasad Paras N; Liebow Charles
Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro.
International journal of oncology 2002;21(6):1325-9.
2002: Kovacs M; Schally A V; Lee E-J; Busto R; Armatis P; Groot K; Varga J L
Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor.
The Journal of endocrinology 2002;175(2):425-34.
2002: Horvath Judit E; Bajo Ana M; Schally Andrew V; Kovacs Magdolna; Herbert Francine; Groot Kate
Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(23):15048-53.
2002: Arencibia Jose M; Bajo Ana M; Schally Andrew V; Krupa Magdalena; Chatzistamou Ioulia; Nagy Attila
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Anti-cancer drugs 2002;13(9):949-56.
2002: Braczkowski Ryszard; Schally Andrew V; Plonowski Artur; Varga Jozsef L; Groot Kate; Krupa Magdalena; Armatis Patricia
Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
Cancer 2002;95(8):1735-45.
2002: Halmos Gabor; Schally Andrew V; Czompoly Tamas; Krupa Magdalena; Varga Jozsef L; Rekasi Zoltan
Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
The Journal of clinical endocrinology and metabolism 2002;87(10):4707-14.
2002: Krebs Linda J; Wang Xiaopeng; Nagy Attila; Schally Andrew V; Prasad Paras N; Liebow Charles
A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers.
Oral oncology 2002;38(7):657-663.
2002: Busto R; Schally A V; Braczkowski R; Plonowski A; Krupa M; Groot K; Armatis P; Varga J L
Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors.
Regulatory peptides 2002;108(2-3):47-53.
2002: Gründker Carsten; Völker Peter; Griesinger Frank; Ramaswamy Annette; Nagy Attila; Schally Andrew V; Emons Günter
Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
American journal of obstetrics and gynecology 2002;187(3):528-37.
2002: Chatzistamou Ioulia; Schally Andrew V; Pafiti Agatha; Kiaris Hippokratis; Koutselini Helen
Expression of growth hormone-releasing hormone in human primary endometrial carcinomas.
European journal of endocrinology / European Federation of Endocrine Societies 2002;147(3):381-6.
2002: Busto Rebeca; Schally Andrew V; Varga Jozsef L; Garcia-Fernandez M Olga; Groot Kate; Armatis Patricia; Szepeshazi Karoly
The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11866-71.
2002: Tang Xiaohui; Yano Tetsu; Osuga Yutaka; Matsumi Hirotaka; Yano Naomi; Xu Jiping; Wada Osamu; Koga Kaori; Kugu Koji; Tsutsumi Osamu; Schally Andrew V; Taketani Yuji
Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix.
The Journal of clinical endocrinology and metabolism 2002;87(8):3721-7.
2002: Plonowski Artur; Schally Andrew V; Letsch Markus; Krupa Magdalena; Hebert Francine; Busto Rebeca; Groot Kate; Varga Jozsef L
Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
The Prostate 2002;52(3):173-82.
2002: Plonowski Artur; Schally Andrew V; Busto Rebeca; Krupa Magdalena; Varga Jozsef L; Halmos Gabor
Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.
Peptides 2002;23(6):1127-33.
2002: Huang Ying-Tang; Hwang Jiuan-Jiuan; Lee Lung-Ta; Liebow Charles; Lee Ping-Ping H; Ke Ferng-Chun; Lo Tung-Bin; Schally Andrew V; Lee Ming-Ting
Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells.
International journal of cancer. Journal international du cancer 2002;99(4):505-13.
2002: Szereday Z; Schally A V; Nagy A; Plonowski A; Bajo A M; Halmos G; Szepeshazi K; Groot K
Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
British journal of cancer 2002;86(8):1322-7.
2002: Plonowski Artur; Varga Jozsef L; Schally Andrew V; Krupa Magdalena; Groot Kate; Halmos Gabor
Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
International journal of cancer. Journal international du cancer 2002;98(4):624-9.
2002: Bajo Ana M; Schally Andrew V; Krupa Magdalena; Hebert Francine; Groot Kate; Szepeshazi Karoly
Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(6):3836-41.
2002: Matsuo H; Baba Y; Nair R M G; Arimura A; Schally A V
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. 1991.
The Journal of urology 2002;167(2 Pt 2):1011-4; discussion 1015.
2002: Szepeshazi Karoly; Schally Andrew V; Halmos Gabor; Armatis Patricia; Hebert Francine; Sun Baodong; Feil Anita; Kiaris Hippokratis; Nagy Attila
Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status.
Cancer research 2002;62(3):781-8.
2002: Plonowski Artur; Schally Andrew V; Nagy Attila; Groot Kate; Krupa Magdalena; Navone Nora M; Logothetis Christopher
Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Cancer letters 2002;176(1):57-63.
2002: Plonowski Artur; Schally Andrew V; Nagy Attila; Sun Baodong; Halmos Gabor
Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
International journal of oncology 2002;20(2):397-402.
2002: Kovacs M; Schally A V; Csernus B; Busto R; Rekasi Z; Nagy A
Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.
Journal of neuroendocrinology 2002;14(1):5-13.
2002: Schally Andrew V; Gual Carlos
[Anthology of the first clinical studies with hypothalamic hormones: a story of successful international cooperation]
Gaceta médica de México 2002;138(1):89-100.
2002: Halmos Gabor; Schally Andrew V
Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(2):961-5.
2002: Kiaris Hippokratis; Schally Andrew V; Busto Rebeca; Halmos Gabor; Artavanis-Tsakonas Spyros; Varga Jozsef L
Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(1):196-200.
2001: Chatzistamou I; Schally A V; Varga J L; Groot K; Armatis P; Bajo A M
Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Journal of cancer research and clinical oncology 2001;127(11):645-52.
2001: Chatzistamou I; Schally A V; Varga J L; Groot K; Busto R; Armatis P; Halmos G
Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone.
Anti-cancer drugs 2001;12(9):761-8.
2001: Kovacs M; Schally A V
Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(21):12197-202.
2001: Schally A V; Comaru-Schally A M; Nagy A; Kovacs M; Szepeshazi K; Plonowski A; Varga J L; Halmos G
Hypothalamic hormones and cancer.
Frontiers in neuroendocrinology 2001;22(4):248-91.
2001: Szepeshazi K; Schally A V; Armatis P; Groot K; Hebert F; Feil A; Varga J L; Halmos G
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
Endocrinology 2001;142(10):4371-8.
2001: Plonowski A; Schally A V; Koppan M; Nagy A; Arencibia J M; Csernus B; Halmos G
Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.
Cancer 2001;92(5):1168-76.
2001: Szepeshazi K; Schally A V; Halmos G; Sun B; Hebert F; Csernus B; Nagy A
Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2854-61.
2001: Arencibia J M; Schally A V; Krupa M; Bajo A M; Nagy A; Szepeshazi K; Plonowski A
Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
International journal of oncology 2001;19(3):571-7.
2001: Chatzistamou I; Schally A V; Szepeshazi K; Groot K; Hebert F; Arencibia J M
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
Cancer letters 2001;171(1):37-45.
2001: Rekasi Z; Schally A V; Plonowski A; Czompoly T; Csernus B; Varga J L
Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
The Prostate 2001;48(3):188-99.
2001: Wang X; Pudavar H E; Kapoor R; Krebs L J; Bergey E J; Liebow C; Prasad P N; Nagy A; Schally A V
Studies on the mechanism of action of a targeted chemotherapeutic drug in living cancer cells by two photon laser scanning microspectrofluorometry.
Journal of biomedical optics 2001;6(3):319-25.
2001: Rekasi Z; Varga J L; Schally A V; Plonowski A; Halmos G; Csernus B; Armatis P; Groot K
Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Peptides 2001;22(6):879-86.
2001: Diedrich K; Frydman R; Devroey P; Felberbaum R; Schally A V; Reissmann T; Engel J
Comment on the debate article: embryo implantation: the Rubicon for GnRH antagonists.
Human reproduction (Oxford, England) 2001;16(6):1305-6.
2001: Chatzistamou I; Schally A V; Varga J L; Groot K; Armatis P; Busto R; Halmos G
Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
The Journal of clinical endocrinology and metabolism 2001;86(5):2144-52.
2001: Yakar S; Liu J L; Fernandez A M; Wu Y; Schally A V; Frystyk J; Chernausek S D; Mejia W; Le Roith D
Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity.
Diabetes 2001;50(5):1110-8.
2001: Schally A; Nagy A
Targeted cytotoxic analogs of luteinizing hormone-releasing hormone: a reply.
European journal of endocrinology / European Federation of Endocrine Societies 2001;144(5):559.
2001: Murphy L O; Cluck M W; Lovas S; Otvös F; Murphy R F; Schally A V; Permert J; Larsson J; Knezetic J A; Adrian T E
Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions.
British journal of cancer 2001;84(7):926-35.
2001: Puente E; Saint-Laurent N; Torrisani J; Furet C; Schally A V; Vaysse N; Buscail L; Susini C
Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta. Involvement of Smad4.
The Journal of biological chemistry 2001;276(16):13461-8.
2001: Kiaris H; Schally A V; Nagy A; Szepeshazi K; Hebert F; Halmos G
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
European journal of cancer (Oxford, England : 1990) 2001;37(5):620-8.
2001: Kovacs M; Schally A V; Csernus B; Rekasi Z
Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(4):1829-34.
2001: Arencibia J M; Schally A V; Halmos G; Nagy A; Kiaris H
In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Anti-cancer drugs 2001;12(1):71-8.
2001: Kiaris H; Schally A V; Armatis P
Direct action of growth hormone-releasing hormone agonist JI-38 on normal human fibroblasts: evidence from studies on cell proliferation and c-myc proto-oncogene expression.
Regulatory peptides 2001;96(3):119-24.
2001: O'Byrne K J; Schally A V; Thomas A; Carney D N; Steward W P
Somatostatin, its receptors and analogs, in lung cancer.
Chemotherapy 2001;47 Suppl 2():78-108.
2000: Kiaris H; Schally A V; Varga J L
Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma.
Cancer letters 2000;161(2):149-55.
2000: Plonowski A; Nagy A; Schally A V; Sun B; Groot K; Halmos G
In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215.
International journal of cancer. Journal international du cancer 2000;88(4):652-7.
2000: Westphalen S; Kotulla G; Kaiser F; Krauss W; Werning G; Elsasser H P; Nagy A; Schulz K D; Grundker C; Schally A V; Emons G
Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines.
International journal of oncology 2000;17(5):1063-9.
2000: Halmos G; Sun B; Schally A V; Hebert F; Nagy A
Human ovarian cancers express somatostatin receptors.
The Journal of clinical endocrinology and metabolism 2000;85(10):3509-12.
2000: Chatzistamou L; Schally A V; Nagy A; Armatis P; Szepeshazi K; Halmos G
Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):4158-65.
2000: Schally A V; Comaru-Schally A M; Plonowski A; Nagy A; Halmos G; Rekasi Z
Peptide analogs in the therapy of prostate cancer.
The Prostate 2000;45(2):158-66.
2000: Chatzistamou I; Schally A V; Sun B; Armatis P; Szepeshazi K
Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
British journal of cancer 2000;83(7):906-13.
2000: Schally A V
Use of GnRH in preference to LH-RH terminology in scientific papers.
Human reproduction (Oxford, England) 2000;15(9):2059-61.
2000: Rekasi Z; Czompoly T; Schally A V; Halmos G
Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(19):10561-6.
2000: Halmos G; Schally A V; Varga J L; Plonowski A; Rekasi Z; Czompoly T
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(19):10555-60.
2000: Krebs L J; Wang X; Pudavar H E; Bergey E J; Schally A V; Nagy A; Prasad P N; Liebow C
Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
Cancer research 2000;60(15):4194-9.
2000: Benali N; Cordelier P; Calise D; Pages P; Rochaix P; Nagy A; Esteve J P; Pour P M; Schally A V; Vaysse N; Susini C; Buscail L
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(16):9180-5.
2000: Halmos G; Schally A V; Kahan Z
Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix.
International journal of oncology 2000;17(2):367-73.
2000: Reissmann T; Schally A V; Bouchard P; Riethmiiller H; Engel J
The LHRH antagonist cetrorelix: a review.
Human reproduction update 2000;6(4):322-31.
2000: Halmos G; Schally A V; Sun B; Davis R; Bostwick D G; Plonowski A
High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
The Journal of clinical endocrinology and metabolism 2000;85(7):2564-71.
2000: Plonowski A; Schally A V; Varga J L; Rekasi Z; Hebert F; Halmos G; Groot K
Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
The Prostate 2000;44(2):172-80.
2000: Plonowski A; Schally A V; Nagy A; Kiaris H; Hebert F; Halmos G
Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
Cancer research 2000;60(11):2996-3001.
2000: Rekasi Z; Varga J L; Schally A V; Halmos G; Armatis P; Groot K; Czompoly T
Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Endocrinology 2000;141(6):2120-8.
2000: Sun B; Schally A V; Halmos G
The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.
Regulatory peptides 2000;90(1-3):77-84.
2000: Kiaris H; Schally A V; Varga J L
Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice.
Neoplasia (New York, N.Y.) 2000;2(3):242-50.
2000: Szepeshazi K; Schally A V; Groot K; Armatis P; Halmos G; Herbert F; Szende B; Varga J L; Zarandi M
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
British journal of cancer 2000;82(10):1724-31.
2000: Arencibia J M; Schally A V
Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line.
International journal of oncology 2000;16(5):1009-13.
2000: Kovacs M; Kineman R D; Schally A V; Flerko B; Frohman L A
Increase in mRNA concentrations of pituitary receptors for growth hormone-releasing hormone and growth hormone secretagogues after neonatal monosodium glutamate treatment.
Journal of neuroendocrinology 2000;12(4):335-41.
2000: Kahán Z; Varga J L; Schally A V; Rékási Z; Armatis P; Chatzistamou L; Czömpöly T; Halmos G
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Breast cancer research and treatment 2000;60(1):71-9.
2000: Kahán Z; Sun B; Schally A V; Arencibia J M; Cai R Z; Groot K; Halmos G
Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Cancer 2000;88(6):1384-92.
2000: Sun B; Halmos G; Schally A V; Wang X; Martinez M
Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.
The Prostate 2000;42(4):295-303.
2000: Kahán Z; Nagy A; Schally A V; Halmos G; Arencibia J M; Groot K
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Breast cancer research and treatment 2000;59(3):255-62.
2000: Kiaris H; Schally A V; Nagy A; Sun B; Szepeshazi K; Halmos G
Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):709-17.
2000: Rekasi Z; Varga J L; Schally A V; Halmos G; Groot K; Czompoly T
Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(3):1218-23.
2000: Halmos G; Arencibia J M; Schally A V; Davis R; Bostwick D G
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
The Journal of urology 2000;163(2):623-9.
2000: Szepeshazi K; Schally A V; Groot K; Armatis P; Hebert F; Halmos G
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(1):128-36.
2000: Nagy A; Plonowski A; Schally A V
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(2):829-34.
2000: Yano T; Radulovic S; Osuga Y; Kugu K; Yoshikawa H; Taketani Y; Schally A V
Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160.
Oncology 2000;59 Suppl 1():45-9.
1999: Schally A V
LH-RH analogues: I. Their impact on reproductive medicine.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1999;13(6):401-9.
1999: Kiaris H; Schally A V; Varga J L; Groot K; Armatis P
Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(26):14894-8.
1999: Kiaris H; Schally A V; Sun B; Armatis P; Groot K
Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
Oncogene 1999;18(50):7168-73.
1999: Kiaris H; Schally A V; Nagy A; Sun B; Armatis P; Szepeshazi K
Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
British journal of cancer 1999;81(6):966-71.
1999: Csernus V; Schally A V; Groot K
Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro.
The Journal of endocrinology 1999;163(2):269-80.
1999: Wang X; Krebs L J; Al-Nuri M; Pudavar H E; Ghosal S; Liebow C; Nagy A A; Schally A V; Prasad P N
A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(20):11081-4.
1999: Mishima M; Yano T; Jimbo H; Yano N; Morita Y; Yoshikawa H; Schally A V; Taketani Y
Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160.
American journal of obstetrics and gynecology 1999;181(3):583-90.
1999: Szepeshazi K; Schally A V; Nagy A
Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs.
Breast cancer research and treatment 1999;56(3):267-76.
1999: Szepesházi K; Halmos G; Schally A V; Arencibia J M; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
Journal of cancer research and clinical oncology 1999;125(8-9):444-52.
1999: Kahán Z; Nagy A; Schally A V; Hebert F; Sun B; Groot K; Halmos G
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
International journal of cancer. Journal international du cancer 1999;82(4):592-8.
1999: Schally A V; Nagy A
Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.
European journal of endocrinology / European Federation of Endocrine Societies 1999;141(1):1-14.
1999: Kahán Z; Nagy A; Schally A V; Halmos G; Arencibia J M; Groot K
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207.
Cancer 1999;85(12):2608-15.
1999: Kiaris H; Schally A V
Apoptosis versus necrosis: which should be the aim of cancer therapy?
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1999;221(2):87-8.
1999: Miyazaki M; Schally A V; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
American journal of obstetrics and gynecology 1999;180(5):1095-103.
1999: Pagès P; Benali N; Saint-Laurent N; Estève J P; Schally A V; Tkaczuk J; Vaysse N; Susini C; Buscail L
sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1.
The Journal of biological chemistry 1999;274(21):15186-93.
1999: Plonowski A; Schally A V; Nagy A; Sun B; Szepeshazi K
Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
Cancer research 1999;59(8):1947-53.
1999: Halmos G; Nagy A; Lamharzi N; Schally A V
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers.
Cancer letters 1999;136(2):129-36.
1999: O'Byrne K J; Dobbs N; Propper D J; Braybrooke J P; Koukourakis M I; Mitchell K; Woodhull J; Talbot D C; Schally A V; Harris A L
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.
British journal of cancer 1999;79(9-10):1413-8.
1999: Csernus V J; Schally A V; Kiaris H; Armatis P
Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(6):3098-103.
1999: Kahán Z; Arencibia J M; Csernus V J; Groot K; Kineman R D; Robinson W R; Schally A V
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers.
The Journal of clinical endocrinology and metabolism 1999;84(2):582-9.
1999: Koppán M; Nagy A; Schally A V; Plonowski A; Halmos G; Arencibia J M; Groot K
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
The Prostate 1999;38(2):151-8.
1999: Varga J L; Schally A V; Csernus V J; Zarándi M; Halmos G; Groot K; Rékási Z
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(2):692-7.
1999: Danila D C; Schally A V; Nagy A; Alexander J M
Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(2):669-73.
1999: Kiaris H; Schally A V
Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(1):226-31.
1999: Schally A V
Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis.
Peptides 1999;20(10):1247-62.
1999: Alvaro-Alonso I; Muñoz-Acedo G; Rodríguez-Martín E; Schally A V; Arilla E
Bombesin induces a reduction of somatostatin inhibition of adenylyl cyclase activity, Gi function, and somatostatin receptors in rat exocrine pancreas.
Peptides 1999;20(6):723-30.
1999: Csernus V; Schally A V; Groot K
Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.
Peptides 1999;20(7):843-50.
1998: Comaru-Schally A M; Brannan W; Schally A V; Colcolough M; Monga M
Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia.
The Journal of clinical endocrinology and metabolism 1998;83(11):3826-31.
1998: Lamharzi N; Schally A V; Koppán M
Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors.
Regulatory peptides 1998;77(1-3):185-92.
1998: Koppán M; Halmos G; Arencibia J M; Lamharzi N; Schally A V
Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
Cancer 1998;83(7):1335-43.
1998: Koppan M; Nagy A; Schally A V; Arencibia J M; Plonowski A; Halmos G
Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
Cancer research 1998;58(18):4132-7.
1998: Lamharzi N; Halmos G; Jungwirth A; Schally A V
Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice.
International journal of oncology 1998;13(3):429-35.
1998: Lamharzi N; Schally A V; Koppán M; Groot K
Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(15):8864-8.
1998: Denmeade S R; Nagy A; Gao J; Lilja H; Schally A V; Isaacs J T
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.
Cancer research 1998;58(12):2537-40.
1998: Miyazaki M; Lamharzi N; Schally A V; Halmos G; Szepeshazi K; Groot K; Cai R Z
Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
European journal of cancer (Oxford, England : 1990) 1998;34(5):710-7.
1998: Jungwirth A; Schally A V; Halmos G; Groot K; Szepeshazi K; Pinski J; Armatis P
Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
Cancer 1998;82(5):909-17.
1998: Lamharzi N; Halmos G; Armatis P; Schally A V
Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines.
International journal of oncology 1998;12(3):671-5.
1998: Srkalovic G; Schally A V; Wittliff J L; Day T G; Jenison E L
Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer.
International journal of oncology 1998;12(3):489-98.
1998: Toth K; Kovacs M; Zarandi M; Halmos G; Groot K; Nagy A; Kele Z; Schally A V
New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.
The journal of peptide research : official journal of the American Peptide Society 1998;51(2):134-41.
1998: Nagy A; Schally A V; Halmos G; Armatis P; Cai R Z; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z
Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1794-9.
1998: Pollak M N; Schally A V
Mechanisms of antineoplastic action of somatostatin analogs.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1998;217(2):143-52.
1997: Miyazaki M; Nagy A; Schally A V; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
Journal of the National Cancer Institute 1997;89(23):1803-9.
1997: Emons G; Ortmann O; Schulz K D; Schally A V
Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells.
Trends in endocrinology and metabolism: TEM 1997;8(9):355-62.
1997: Szepeshazi K; Schally A V; Nagy A; Halmos G; Groot K
Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
Anti-cancer drugs 1997;8(10):974-87.
1997: Kovacs M; Kineman R D; Schally A V; Zarandi M; Groot K; Frohman L A
Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.
Endocrinology 1997;138(11):4536-42.
1997: Szepeshazi K; Schally A V; Halmos G; Lamharzi N; Groot K; Horvath J E
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(20):10913-8.
1997: Gonzalez-Barcena D; Alvarez R B; Ochoa E P; Cornejo I C; Comaru-Schally A M; Schally A V; Engel J; Reissmann T; Riethmüller-Winzen H
Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.
Human reproduction (Oxford, England) 1997;12(9):2028-35.
1997: Cordelier P; Estève J P; Bousquet C; Delesque N; O'Carroll A M; Schally A V; Vaysse N; Susini C; Buscail L
Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(17):9343-8.
1997: Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai R Z; Groot K; Schally A V
Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
The Prostate 1997;32(3):164-72.
1997: Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai R Z; Groot K; Vadillo-Buenfil M; Schally A V
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
European journal of cancer (Oxford, England : 1990) 1997;33(7):1141-8.
1997: Jungwirth A; Schally A V; Pinski J; Groot K; Armatis P; Halmos G
Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(11):5810-3.
1997: Kovacs M; Schally A V; Nagy A; Koppan M; Groot K
Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(4):1420-5.
1997: Halmos G; Schally A V
Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(3):956-60.
1997: Thakur M L; Kolan H; Li J; Wiaderkiewicz R; Pallela V R; Duggaraju R; Schally A V
Radiolabeled somatostatin analogs in prostate cancer.
Nuclear medicine and biology 1997;24(1):105-13.
1997: Nagy A; Armatis P; Cai R Z; Szepeshazi K; Halmos G; Schally A V
Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(2):652-6.
1997: Yano T; Yano N; Matsumi H; Morita Y; Tsutsumi O; Schally A V; Taketani Y
Effect of luteinizing hormone-releasing hormone analogs on the rat ovarian follicle development.
Hormone research 1997;48 Suppl 3():35-41.
1997: Jungwirth A; Schally A V; Pinski J; Halmos G; Groot K; Armatis P; Vadillo-Buenfil M
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
British journal of cancer 1997;75(11):1585-92.
1997: Kovács M; Schally A V; Zarándi M; Groot K
Inhibition of GH release of rats by new potent antagonists of growth hormone-releasing hormone (GH-RH).
Peptides 1997;18(3):431-8.
1997: Zarandi M; Kovacs M; Horvath J E; Toth K; Halmos G; Groot K; Nagy A; Kele Z; Schally A V
Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH).
Peptides 1997;18(3):423-30.
1996: Kovacs M; Zarándi M; Halmos G; Groot K; Schally A V
Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
Endocrinology 1996;137(12):5364-9.
1996: Wang Q J; Knezetic J A; Schally A V; Pour P M; Adrian T E
Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway.
International journal of cancer. Journal international du cancer 1996;68(4):528-34.
1996: Emons G; Ortmann O; Teichert H M; Fassl H; Löhrs U; Kullander S; Kauppila A; Ayalon D; Schally A; Oberheuser F
Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group.
Cancer 1996;78(7):1452-60.
1996: Pinski J; Izdebski J; Jungwirth A; Groot K; Schally A V
Effect of chronic administration of a new potent agonist of GH-RH(1-29)NH2 on linear growth and GH responsiveness in rats.
Regulatory peptides 1996;65(3):197-201.
1996: Kovács M; Halmos G; Groot K; Izdebski J; Schally A V
Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action.
Neuroendocrinology 1996;64(3):169-76.
1996: Pinski J; Lamharzi N; Halmos G; Groot K; Jungwirth A; Vadillo-Buenfil M; Kakar S S; Schally A V
Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Endocrinology 1996;137(8):3430-6.
1996: Nagy A; Schally A V; Armatis P; Szepeshazi K; Halmos G; Kovacs M; Zarandi M; Groot K; Miyazaki M; Jungwirth A; Horvath J
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(14):7269-73.
1996: Kozacko M F; Mang T S; Schally A V; Priore R L; Liebow C
Bombesin antagonist prevents CO2 laser-induced promotion of oral cancer.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(7):2953-7.
1996: Nagy A; Armatis P; Schally A V
High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(6):2464-9.
1996: Halmos G; Schally A V; Pinski J; Vadillo-Buenfil M; Groot K
Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(6):2398-402.
1996: Pinski J; Schally A V; Halmos G; Szepeshazi K; Groot K
Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice.
International journal of cancer. Journal international du cancer 1996;65(6):870-4.
1996: Casanueva F F; Perez F R; Casabiell X; Camiña J P; Cai R Z; Schally A V
Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(4):1406-11.
1996: Szepeshazi K; Schally A V; Halmos G; Szoke B; Groot K; Nagy A
Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.
Breast cancer research and treatment 1996;40(2):129-39.
1995: Pinski J; Schally A V; Groot K; Halmos G; Szepeshazi K; Zarandi M; Armatis P
Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.
Journal of the National Cancer Institute 1995;87(23):1787-94.
1995: Qin Y; Ertl T; Cai R Z; Horvàth J E; Groot K; Schally A V
Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP.
International journal of cancer. Journal international du cancer 1995;63(2):257-62.
1995: Horváth J E; Zarándi M; Groot K; Schally A V
Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.
Endocrinology 1995;136(9):3849-55.
1995: Reissmann T; Felberbaum R; Diedrich K; Engel J; Comaru-Schally A M; Schally A V
Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview.
Human reproduction (Oxford, England) 1995;10(8):1974-81.
1995: Schally A V; McCann S M
The privileges of a Nobel laureate.
Fertility and sterility 1995;64(2):452-3.
1995: Schally A V; Halmos G; Pinski J
Terminology for luteinizing hormone-releasing hormone antagonists.
Fertility and sterility 1995;64(1):226.
1995: Groot K; Horvàth J E; Cai R Z; Schally A V
Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity.
International journal of peptide and protein research 1995;45(6):561-6.
1995: Izdebski J; Pinski J; Horvath J E; Halmos G; Groot K; Schally A V
Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(11):4872-6.
1995: Pinski J; Schally A V; Yano T; Groot K; Srkalovic G; Serfozo P; Reissmann T; Bernd M; Deger W; Kutscher B
Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).
International journal of peptide and protein research 1995;45(5):410-7.
1995: Konturek S J; Brzozowski T; Bielanski W; Schally A V
Role of endogenous gastrin in gastroprotection.
European journal of pharmacology 1995;278(3):203-12.
1995: Sanchez-Garrido F; Comaru-Schally A M; Sanchez del Cura G; Gonzales-Enriquez J; Schally A V
Clearance of lung metastases of breast carcinoma after treatment with triptorelin in postmenopausal woman.
Lancet 1995;345(8953):868.
1995: Horváth J E; Groot K; Schally A V
Growth hormone-releasing hormone stimulates cAMP release in superfused rat pituitary cells.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(6):1856-60.
1995: Qin Y; Ertl T; Groot K; Horvath J; Cai R Z; Schally A V
Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate.
International journal of cancer. Journal international du cancer 1995;60(5):694-700.
1995: Buscail L; Estève J P; Saint-Laurent N; Bertrand V; Reisine T; O'Carroll A M; Bell G I; Schally A V; Vaysse N; Susini C
Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(5):1580-4.
1995: Manetta A; Gamboa-Vujicic G; Paredes P; Emma D; Liao S; Leong L; Asch B; Schally A
Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75).
Fertility and sterility 1995;63(2):282-7.
1995: Gonzalez-Barcena D; Vadillo-Buenfil M; Cortez-Morales A; Fuentes-Garcia M; Cardenas-Cornejo I; Comaru-Schally A M; Schally A V
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.
Urology 1995;45(2):275-81.
1995: Halmos G; Wittliff J L; Schally A V
Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression.
Cancer research 1995;55(2):280-7.
1995: Crean D H; Liebow C; Lee M T; Kamer A R; Schally A V; Mang T S
Alterations in receptor-mediated kinases and phosphatases during carcinogenesis.
Journal of cancer research and clinical oncology 1995;121(3):141-9.
1995: Chang C F; Yueh W S; Lee M F; Schally A V
A microencapsulated analog of LH-RH accelerates maturation but without stimulating sex reversal in the protandrous black porgy, Acanthopagrus schlegeli.
Reproduction, nutrition, development 1995;35(3):339-50.
1995: Delesque N; Buscail L; Estève J P; Rauly I; Zeggari M; Saint-Laurent N; Bell G I; Schally A V; Vaysse N; Susini C
A tyrosine phosphatase is associated with the somatostatin receptor.
Ciba Foundation symposium 1995;190():187-96; discussion 196-203.
1994: Zarandi M; Horvath J E; Halmos G; Pinski J; Nagy A; Groot K; Rekasi Z; Schally A V
Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(25):12298-302.
1994: Cai R Z; Reile H; Armatis P; Schally A V
Potent bombesin antagonists with C-terminal Leu-psi(CH2-N)-Tac-NH2 or its derivatives.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(26):12664-8.
1994: Pinski J; Schally A V; Halmos G; Szepeshazi K; Groot K
Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
Cancer research 1994;54(22):5895-901.
1994: Pinski J; Schally A V; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai R Z
Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
British journal of cancer 1994;70(5):886-92.
1994: Pinski J; Reile H; Halmos G; Groot K; Schally A V
Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
International journal of cancer. Journal international du cancer 1994;59(1):51-5.
1994: Szepshazi K; Halmos G; Groot K; Schally A V
Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
International journal of pancreatology : official journal of the International Association of Pancreatology 1994;16(2-3):141-9.
1994: Halmos G; Pinski J; Szoke B; Schally A V
Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer.
Cancer letters 1994;85(1):111-8.
1994: Gonzalez-Barcena D; Vadillo Buenfil M; Garcia Procel E; Guerra-Arguero L; Cardenas Cornejo I; Comaru-Schally A M; Schally A V
Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75).
European journal of endocrinology / European Federation of Endocrine Societies 1994;131(3):286-92.
1994: Reile H; Armatis P E; Schally A V
Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells.
The Prostate 1994;25(1):29-38.
1994: Emons G; Schally A V
The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.
Human reproduction (Oxford, England) 1994;9(7):1364-79.
1994: Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally A V
Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(15):7090-4.
1994: Reissmann T; Diedrich K; Comaru-Schally A M; Schally A V
Introduction of LHRH-antagonists into the treatment of gynaecological disorders.
Human reproduction (Oxford, England) 1994;9(5):769.
1994: Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally A V
Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
International journal of cancer. Journal international du cancer 1994;57(4):574-80.
1994: Liebow C; Crean D H; Lee M T; Kamer A R; Mang T S; Schally A V
Synergistic effects of bombesin and epidermal growth factor on cancers.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(9):3804-8.
1994: Schally A V
Hypothalamic hormones: from neuroendocrinology to cancer therapy.
Anti-cancer drugs 1994;5(2):115-30.
1994: Varnum J M; Thakur M L; Schally A V; Jansen S; Mayo K H
Rhenium-labeled somatostatin analog RC-160. 1H NMR and computer modeling conformational analysis.
The Journal of biological chemistry 1994;269(17):12583-8.
1994: Yano T; Pinski J; Radulovic S; Schally A V
Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(5):1701-5.
1994: Müller A; Busker E; Engel J; Kutscher B; Bernd M; Schally A V
Structural investigation of Cetrorelix, a new potent and long-acting LH-RH antagonist.
International journal of peptide and protein research 1994;43(3):264-70.
1994: Buscail L; Delesque N; Estève J P; Saint-Laurent N; Prats H; Clerc P; Robberecht P; Bell G I; Liebow C; Schally A V
Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(6):2315-9.
1994: Qin Y; Ertl T; Cai R Z; Halmos G; Schally A V
Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
Cancer research 1994;54(4):1035-41.
1994: Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally A V
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
Cancer 1994;73(4):1229-38.
1994: Kleinman D; Douvdevani A; Schally A V; Levy J; Sharoni Y
Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis.
American journal of obstetrics and gynecology 1994;170(1 Pt 1):96-102.
1994: Pinski J; Reile H; Halmos G; Groot K; Schally A V
Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
Cancer research 1994;54(1):169-74.
1994: Qin Y; Halmos G; Cai R Z; Szoke B; Ertl T; Schally A V
Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors.
Journal of cancer research and clinical oncology 1994;120(9):519-28.
1994: Szöke B; Horváth J; Halmos G; Rékási Z; Groot K; Nagy A; Schally A V
LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro.
Peptides 1994;15(2):359-66.
1994: Banks W A; Kastin A J; Sam H M; Cao V T; King B; Maness L M; Schally A V
Saturable efflux of the peptides RC-160 and Tyr-MIF-1 by different parts of the blood-brain barrier.
Brain research bulletin 1994;35(2):179-82.
1994: Radulovic S; Schally A V; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T
Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
Acta oncologica (Stockholm, Sweden) 1994;33(6):693-701.
1994: Szende B; Csikós A; Szepeshazi K; Neill J D; Mulchahey J J; Halmos G; Lapis K; Schally A V
The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters.
Receptor 1994;4(4):201-7.
1994: Shirahige Y; Cai R Z; Szepeshazi K; Halmos G; Pinski J; Groot K; Schally A V
Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1994;48(10):465-72.
1994: O'Byrne K J; Halmos G; Pinski J; Groot K; Szepeshazi K; Schally A V; Carney D N
Somatostatin receptor expression in lung cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(11):1682-7.
1994: Horváth J E; Schally A V
Reciprocal changes in prolactin and growth hormone secretion in vitro after in vivo estrogen treatment.
Acta biologica Hungarica 1994;45(2-4):249-62.
1994: Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally A M; Schally A V
Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
The Prostate 1994;24(2):84-92.
1993: Emons G; Schröder B; Ortmann O; Westphalen S; Schulz K D; Schally A V
High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
The Journal of clinical endocrinology and metabolism 1993;77(6):1458-64.
1993: Pinski J; Halmos G; Szepeshazi K; Schally A V
Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Cancer 1993;72(11):3263-70.
1993: Pinski J; Schally A V; Halmos G; Szepeshazi K
Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
International journal of cancer. Journal international du cancer 1993;55(6):963-7.
1993: Emons G; Ortmann O; Becker M; Irmer G; Springer B; Laun R; Hölzel F; Schulz K D; Schally A V
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
Cancer research 1993;53(22):5439-46.
1993: Pinski J; Halmos G; Shirahige Y; Wittliff J L; Schally A V
Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486.
The Journal of clinical endocrinology and metabolism 1993;77(5):1388-92.
1993: Hershkovitz E; Marbach M; Bosin E; Levy J; Roberts C T; LeRoith D; Schally A V; Sharoni Y
Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors.
The Journal of clinical endocrinology and metabolism 1993;77(4):963-8.
1993: Kleinman D; Roberts C T; LeRoith D; Schally A V; Levy J; Sharoni Y
Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75.
Regulatory peptides 1993;48(1-2):91-8.
1993: Ayalon D; Farhi Y; Comaru-Schally A M; Schally A V; Eckstein N; Vagman I; Limor R
Inhibitory effect of a highly potent antagonist of LH releasing hormone (SB-75) on the pituitary gonadal axis in the intact and castrated rat.
Neuroendocrinology 1993;58(2):153-9.
1993: Pinski J; Halmos G; Schally A V
Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
Cancer letters 1993;71(1-3):189-96.
1993: Nagy A; Szoke B; Schally A V
Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(13):6373-6.
1993: Rékási Z; Szöke B; Nagy A; Groot K; Rékási E S; Schally A V
Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system.
Endocrinology 1993;132(5):1991-2000.
1993: Pinski J; Yano T; Szepeshazi K; Groot K; Schally A V
Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75).
Journal of andrology 1993;14(3):164-9.
1993: Szepeshazi K; Schally A V; Groot K; Halmos G
Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
International journal of cancer. Journal international du cancer 1993;54(2):282-9.
1993: Pinski J; Yano T; Groot K; Zsigo J; Rekasi Z; Comaru-Schally A M; Schally A V
Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats.
International journal of peptide and protein research 1993;41(3):246-9.
1993: Rekasi Z; Schally A V
A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(6):2146-9.
1993: Konturek S J; Tasler J; Bilski J; Cieszkowski M; Cai R Z; Schally A V
Antagonism of receptors for gastrin, cholecystokinin and GRP/bombesin in postprandial stimulation of exocrine pancreas in dogs.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 1993;44(1):43-53.
1993: Liebow C; Crean D H; Schally A V; Mang T S
Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(5):1897-901.
1993: Groot K; Csernus V J; Pinski J; Zsigo J; Rekasi Z; Zarandi M; Schally A V
Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone.
International journal of peptide and protein research 1993;41(2):162-8.
1993: Pinski J; Yano T; Janaky T; Nagy A; Juhasz A; Bokser L; Groot K; Schally A V
Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.
International journal of peptide and protein research 1993;41(1):66-73.
1993: Radulovic S; Comaru-Schally A M; Milovanovic S; Schally A V
Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Pancreas 1993;8(1):88-97.
1993: Milovanovic S R; Monje E; Szepeshazi K; Radulovic S; Schally A
Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.
Journal of cancer research and clinical oncology 1993;119(5):273-8.
1993: Pinski J; Schally A V; Yano T; Szepeshazi K; Halmos G; Groot K; Comaru-Schally A M; Radulovic S; Nagy A
Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals.
The Prostate 1993;23(2):165-78.
1993: Halmos G; Rekasi Z; Szoke B; Schally A V
Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone.
Receptor 1993;3(2):87-97.
1992: Roberge S; Schramm R D; Schally A V; Reeves J J
Reduced postpartum anestrus of suckled beef cows treated with microencapsulated luteinizing hormone-releasing hormone analog.
Journal of animal science 1992;70(12):3825-30.
1992: Szepeshazi K; Schally A V; Halmos G; Groot K; Radulovic S
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Journal of the National Cancer Institute 1992;84(24):1915-22.
1992: Pinski J; Yano T; Schally A V
Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats.
Neuroendocrinology 1992;56(6):831-7.
1992: Qin Y; Schally A V; Willems G
Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160.
International journal of cancer. Journal international du cancer 1992;52(5):791-6.
1992: Qin Y; Van Cauteren M; Osteaux M; Schally A V; Willems G
Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging.
Cancer research 1992;52(21):6025-30.
1992: Pinski J; Yano T; Rekasi Z; Cai R Z; Radulovic S; Schally A V
High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration.
Regulatory peptides 1992;41(3):185-93.
1992: Pinski J; Yano T; Groot K; Cai R Z; Radulovic S; Schally A V
Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
The American journal of physiology 1992;263(4 Pt 1):E712-7.
1992: Banks W A; Kastin A J; Radulovic S; Conley F K; Johnson D L; Schally A V
Selective uptake of the somatostatin analog RC-160 across the blood-brain tumor barrier of mice with KHT sarcomas.
Anti-cancer drugs 1992;3(5):519-23.
1992: Pinski J; Yano T; Groot K; Milovanovic S; Schally A V
Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats.
Peptides 1992;13(5):905-11.
1992: Yano T; Pinski J; Groot K; Schally A V
Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines.
Cancer research 1992;52(16):4545-7.
1992: Csernus V J; Schally A V
Evaluation of luteinizing hormone-releasing hormone antagonistic activity in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(13):5759-63.
1992: Zarandi M; Serfozo P; Zsigo J; Deutch A H; Janaky T; Olsen D B; Bajusz S; Schally A V
Potent agonists of growth hormone-releasing hormone. II.
Peptide research 1992;5(4):190-3.
1992: Girard P M; Goldschmidt E; Vittecoq D; Massip P; Gastiaburu J; Meyohas M C; Coulaud J P; Schally A V
Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases.
AIDS (London, England) 1992;6(7):715-8.
1992: Radulovic S S; Milovanovic S R; Cai R Z; Schally A V
The binding of bombesin and somatostatin and their analogs to human colon cancers.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1992;200(3):394-401.
1992: Roberge S; Johnson H E; Zarandi M; Schally A V; Reeves J J
Evaluation of the biological potency of new agmatine analogs of growth hormone-releasing hormone in the bovine.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1992;200(1):109-14.
1992: Redding T W; Schally A V; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs J T
Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
Cancer research 1992;52(9):2538-44.
1992: Pinski J; Milovanovic S; Yano T; Hamaoui A; Radulovic S; Cai R Z; Schally A V
Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1992;200(1):49-56.
1992: Kádár T; Telegdy G; Schally A V
An LH-RH antagonist inhibits the behavioral effects of the agonist D-TRP-6-LH-RH in mice.
Pharmacology, biochemistry, and behavior 1992;41(4):665-8.
1992: Szepeshazi K; Schally A V; Juhasz A; Nagy A; Janaky T
Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo.
Anti-cancer drugs 1992;3(2):109-16.
1992: Jaworek J; Konturek P K; Konturek S J; Cai R Z; Schally A V
Actions of novel bombesin receptor antagonists on pancreatic secretion in rats.
European journal of pharmacology 1992;214(2-3):239-45.
1992: Cai R Z; Radulovic S; Pinski J; Nagy A; Redding T W; Olsen D B; Schally A V
Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi.
Peptides 1992;13(2):267-71.
1992: Zarandi M; Serfozo P; Zsigo J; Bokser L; Janaky T; Olsen D B; Bajusz S; Schally A V
Potent agonists of growth hormone-releasing hormone. Part I.
International journal of peptide and protein research 1992;39(3):211-7.
1992: Kádár T; Telegdy G; Schally A V
Behavioral effects of centrally administered LH-RH agonist in rats.
Physiology & behavior 1992;51(3):601-5.
1992: Radulovic S; Nagy A; Szoke B; Schally A V
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
Cancer letters 1992;62(3):263-71.
1992: Segal-Abramson T; Kitroser H; Levy J; Schally A V; Sharoni Y
Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(6):2336-9.
1992: Brower S T; Schally A V; Redding T W; Hollander V P
Differential effects of LHRH and somatostatin analogs on human breast cancer.
The Journal of surgical research 1992;52(1):6-14.
1992: Milovanovic S R; Radulovic S; Schally A V
Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor.
Breast cancer research and treatment 1992;24(2):147-58.
1992: Pinski J; Yano T; Miller G; Schally A V
Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75.
The Prostate 1992;20(3):213-24.
1992: Reissmann T; Hilgard P; Harleman J H; Engel J; Comaru-Schally A M; Schally A V
Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
Journal of cancer research and clinical oncology 1992;118(1):44-9.
1992: Calle-Pascual A L; Rodriguez C; Yuste E; de Matias J; Schally A V; Martin-Vaquero P; Castillo P; Charro A L
Effect of the infusion of p-Glu-His-Ala-OH, analog of the anorexigenic peptide, on the insulin response induced by intravenous glucose. Preliminary results with obese subjects.
Hormone and metabolic research. Supplement series 1992;26():27-31.
1992: Yano T; Korkut E; Pinski J; Szepeshazi K; Milovanovic S; Groot K; Clarke R; Comaru-Schally A M; Schally A V
Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH.
Breast cancer research and treatment 1992;21(1):35-45.
1992: Milovanovic S R; Radulovic S; Groot K; Schally A V
Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
The Prostate 1992;20(4):269-80.
1992: Schally A V; Comaru-Schally A M; Gonzalez-Barcena D
Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1992;46(10):465-71.
1992: Szende B; Juhasz E; Lapis K; Schally A V
Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160.
Urological research 1992;20(6):383-6.
1992: Szepeshazi K; Milovanovic S; Lapis K; Groot K; Schally A V
Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.
Breast cancer research and treatment 1992;21(3):181-92.
1992: Yano T; Pinski J; Szepeshazi K; Milovanovic S R; Groot K; Schally A V
Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
The Prostate 1992;20(4):297-310.
1991: Korkut E; Comaru-Schally A M; Schally A V; Plowman P N
LHRH analogues and breast cancer.
British journal of cancer 1991;64(6):1190.
1991: Radulovic S; Cai R Z; Serfozo P; Groot K; Redding T W; Pinski J; Schally A V
Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi.
International journal of peptide and protein research 1991;38(6):593-600.
1991: Radulovic S; Miller G; Schally A V
Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
Cancer research 1991;51(21):6006-9.
1991: Szepeshazi K; Schally A V; Cai R Z; Radulovic S; Milovanovic S; Szoke B
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
Cancer research 1991;51(21):5980-6.
1991: Pour P M; Groot K; Kazakoff K; Anderson K; Schally A V
Effects of high-fat diet on the patterns of prostatic cancer induced in rats by N-nitrosobis(2-oxopropyl)amine and testosterone.
Cancer research 1991;51(18):4757-61.
1991: Szepeshazi K; Lapis K; Schally A V
Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
International journal of cancer. Journal international du cancer 1991;49(2):260-6.
1991: Dembinski A; Warzecha Z; Konturek S J; Banas M; Cai R Z; Schally A V
The effect of antagonist of receptors for gastrin, cholecystokinin and bombesin on growth of gastroduodenal mucosa and pancreas.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 1991;42(3):263-77.
1991: Bokser L; Srkalovic G; Szepeshazi K; Schally A V
Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
Neuroendocrinology 1991;54(2):136-45.
1991: Dembinski A; Warzecha Z; Konturek S J; Cai R Z; Schally A V
The effects of antagonists of receptors for gastrin, cholecystokinin and bombesin on growth of gastroduodenal mucosa and pancreas.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 1991;42(2):195-209.
1991: Schally A V; Guoth J G; Redding T W; Groot K; Rodriguez H; Szonyi E; Stults J; Nikolics K
Isolation and characterization of two peptides with prolactin release-inhibiting activity from porcine hypothalami.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(9):3540-4.
1991: Monsonego J; Destable M D; De Saint Florent G; Amouroux J; Kouyoundjian J C; Haour F; Breau J L; Israel L; Comaru-Schally A M; Schally A V
Fibrocystic disease of the breast in premenopausal women: histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment.
American journal of obstetrics and gynecology 1991;164(5 Pt 1):1181-9.
1991: Szende B; Srkalovic G; Timar J; Mulchahey J J; Neill J D; Lapis K; Csikos A; Szepeshazi K; Schally A V
Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(10):4153-6.
1991: Szepeshazi K; Korkut E; Schally A V
Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone.
The American journal of pathology 1991;138(5):1273-7.
1991: Liebow C; Lee M T; Kamer A R; Schally A V
Regulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(6):2244-8.
1991: Qin Y; Schally A V; Willems G
Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats.
International journal of cancer. Journal international du cancer 1991;47(5):765-70.
1991: Lee M T; Liebow C; Kamer A R; Schally A V
Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(5):1656-60.
1991: Korkut E; Bokser L; Comaru-Schally A M; Groot K; Schally A V
Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(3):844-8.
1991: Szepeshazi K; Korkut E; Szende B; Lapis K; Schally A V
Histological changes in Dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75.
The Prostate 1991;18(3):255-70.
1991: Konturek S J; Bilski J; Hladij M; Krzyzek E; Cai R Z; Schally A V
Role of cholecystokinin, gastrin and gastrin-releasing peptide in the regulation of pancreatic secretion in cats.
Digestion 1991;49(2):97-105.
1991: Konturek S J; Dembinski A; Warzecha Z; Jaworek J; Konturek P K; Cai R Z; Schally A V
Antagonism of receptors for bombesin, gastrin and cholecystokinin in pancreatic secretion and growth.
Digestion 1991;48(2):89-97.
1991: Szende B; Schally A V; Lapis K
Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours.
Acta morphologica Hungarica 1991;39(1):53-8.
1990: Srkalovic G; Bokser L; Radulovic S; Korkut E; Schally A V
Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75.
Endocrinology 1990;127(6):3052-60.
1990: Zarandi M; Csernus V; Bokser L; Bajusz S; Groot K; Schally A V
Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine.
International journal of peptide and protein research 1990;36(6):499-505.
1990: Varea J; Paredes M; Garces G; Ochoa C; Avila C; Coloma M J; Briones R; Comaru-Schally A M; Schally A V
Effect of Somatostatin on TSH levels in non-toxic sporadic goiter.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1990;22(12):627-31.
1990: Schally A V; Srkalovic G; Szende B; Redding T W; Janaky T; Juhasz A; Korkut E; Cai R Z; Szepeshazi K; Radulovic S
Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
The Journal of steroid biochemistry and molecular biology 1990;37(6):1061-7.
1990: Kádár T; Telegdy G; Schally A V
Neuropharmacological actions of the superactive agonist analog D-TRP-6-LH-RH after peripheral injection into mice.
Neuropeptides 1990;17(2):81-6.
1990: Bokser L; Bajusz S; Groot K; Schally A V
Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(18):7100-4.
1990: Schally A V; Colaluca J; Paulson D; Carter W H; Neitzschman H R; Lafaye H; Cai R Z
Effect of somatostatin analogs on gastric acid secretion in dogs and rats.
International journal of peptide and protein research 1990;36(3):267-74.
1990: Liebow C; Lee M T; Schally A
Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase.
Metabolism: clinical and experimental 1990;39(9 Suppl 2):163-6.
1990: Banks W A; Schally A V; Barrera C M; Fasold M B; Durham D A; Csernus V J; Groot K; Kastin A J
Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(17):6762-6.
1990: Redding T W; Schally A V
Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists.
The Journal of endocrinology 1990;126(2):309-15.
1990: Szende B; Srkalovic G; Groot K; Lapis K; Schally A V
Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
Cancer research 1990;50(12):3716-21.
1990: Csernus V J; Szende B; Schally A V
Release of peptides from sustained delivery systems (microcapsules and microparticles) in vivo. A histological and immunohistochemical study.
International journal of peptide and protein research 1990;35(6):557-65.
1990: Bokser L; Szende B; Schally A V
Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.
British journal of cancer 1990;61(6):861-5.
1990: Szende B; Srkalovic G; Schally A V; Lapis K; Groot K
Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression.
Cancer 1990;65(10):2279-90.
1990: Szende B; Srkalovic G; Groot K; Lapis K; Schally A V
Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
Journal of the National Cancer Institute 1990;82(6):513-7.
1990: Srkalovic G; Wittliff J L; Schally A V
Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma.
Cancer research 1990;50(6):1841-6.
1990: Zorn J R; Mathieson J; Risquez F; Comaru-Schally A M; Schally A V
Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients.
Fertility and sterility 1990;53(3):401-6.
1990: Srkalovic G; Cai R Z; Schally A V
Evaluation of receptors for somatostatin in various tumors using different analogs.
The Journal of clinical endocrinology and metabolism 1990;70(3):661-9.
1990: Szende B; Redding T W; Schally A V
Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(3):901-3.
1990: Csernus V J; Szende B; Groot K; Redding T W; Schally A V
Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.
Arzneimittel-Forschung 1990;40(2 Pt 1):111-8.
1990: Kádár T; Telegdy G; Schally A V
Partial reversal of behavioral action of the agonist D-Trp-6-LH-RH by naloxone in mice.
Life sciences 1990;46(7):463-70.
1990: Bokser L; Zarandi M; Schally A V
Evaluation of in vivo [corrected] biological activity of new agmatine analogs of growth hormone-releasing hormone (GH-RH)
Life sciences 1990;46(14):999-1005.
1990: Zalatnai A; Schally A V
Hepatic lesions in Syrian golden hamsters with pancreatic carcinoma induced by N-nitrosobis(2-oxopropyl)amine (BOP).
Acta morphologica Hungarica 1990;38(2):119-30.
1989: Szende B; Lapis K; Redding T W; Srkalovic G; Schally A V
Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.
Breast cancer research and treatment 1989;14(3):307-14.
1989: Srkalovic G; Szende B; Redding T W; Groot K; Schally A V
Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1989;192(3):209-18.
1989: Roberts A J; Chang C F; Schally A V; Reeves J J
Luteinizing hormone concentrations in serum of postpartum beef cows injected with microencapsulated luteinizing hormone-releasing hormone analog.
Journal of animal science 1989;67(10):2730-4.
1989: Edwards B F; Redding T W; Schally A V
The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa).
International journal of pancreatology : official journal of the International Association of Pancreatology 1989;5(2):191-201.
1989: Bajusz S; Janaky T; Csernus V J; Bokser L; Fekete M; Srkalovic G; Redding T W; Schally A V
Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(16):6318-22.
1989: Bajusz S; Janaky T; Csernus V J; Bokser L; Fekete M; Srkalovic G; Redding T W; Schally A V
Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(16):6313-7.
1989: Rubio M A; Cabranes J A; Schally A V; Charro A L
Prolactin-lowering effect of luteinizing hormone-releasing hormone agonist administration in prolactinoma patients.
The Journal of clinical endocrinology and metabolism 1989;69(2):444-7.
1989: Szende B; Schally A V; Srkalovic G; Comaru-Schally A M; Wittliff J L
Adverse effect of tamoxifen with LHRH agonist on oestrogen-receptor-negative mammary carcinoma.
Lancet 1989;2(8656):222-3.
1989: Fekete M; Zalatnai A; Schally A V
Presence of membrane binding sites for [D-TRP6]-luteinizing hormone-releasing hormone in experimental pancreatic cancer.
Cancer letters 1989;45(2):87-91.
1989: Zalatnai A; Schally A V
Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules.
Cancer research 1989;49(7):1810-5.
1989: Sharoni Y; Bosin E; Miinster A; Levy J; Schally A V
Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(5):1648-51.
1989: Zalatnai A; Schally A V
Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.
International journal of pancreatology : official journal of the International Association of Pancreatology 1989;4(2):149-60.
1989: Liebow C; Reilly C; Serrano M; Schally A V
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(6):2003-7.
1989: Szende B; Zalatnai A; Schally A V
Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(5):1643-7.
1989: Mathé G; Schally A V; Comaru-Schally A M; Mauvernay R Y; Vovan M L; Machover D; Misset J L; Court B; Bouchard P; Duchier J
Monitoring and treatment of minimal residual cancer of the prostate.
Bulletin de la Société des sciences médicales du Grand-Duché de Luxembourg 1989;126(1):65-74.
1989: Bokser L; Zalatnai A; Schally A V
Inhibition of pituitary-gonadal axis in mice by long-term administration of D-Trp-6-LHRH microcapsules.
Journal of reproduction and fertility 1989;85(2):569-74.
1989: Fekete M; Bajusz S; Groot K; Csernus V J; Schally A V
Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes.
Endocrinology 1989;124(2):946-55.
1989: George M; Lhomme C; Lefort J; Gras C; Comaru-Schally A M; Schally A V
Long-term use of an LH-RH agonist in the management of uterine leiomyomas: a study of 17 cases.
International journal of fertility 1989;34(1):19-24.
1989: Fekete M; Zalatnai A; Comaru-Schally A M; Schally A V
Membrane receptors for peptides in experimental and human pancreatic cancers.
Pancreas 1989;4(5):521-8.
1989: Fekete M; Wittliff J L; Schally A V
Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer.
Journal of clinical laboratory analysis 1989;3(3):137-47.
1989: González-Barcena D; Ibarra-Olmos M A; García-Carrasco F; Gutiérrez-Samperio C; Comaru-Schally A M; Schally A V
Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1989;43(4):313-7.
1989: Gonzalez-Barcena D; Perez-Sanchez P L; Graef A; Gomez A M; Berea H; Comaru-Schally A M; Schally A V
Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
The Prostate 1989;14(4):291-300.
1989: Fekete M; Redding T W; Comaru-Schally A M; Pontes J E; Connelly R W; Srkalovic G; Schally A V
Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.
The Prostate 1989;14(3):191-208.
1988: Rodríguez Arnao M D; Rodríguez Sánchez M D; González Sicilia I G; Lorenzo Navarro L; Nieto Cuartero J; Schally A V; Rodríguez Arnao J; García Centenera J A; Gómez Pan A
[Therapeutic effectiveness of the gonadotropin releasing hormone analogue D-Trp-6-LHRH in the treatment of precocious puberty]
Anales españoles de pediatría 1988;29(6):445-51.
1988: Ayalon D; Ben-David M; Wohl R; Jaffe R; Vagman I; Eckstein N; Limor R; Comaru-Schally A M; Schally A V
Induction of ovulation with D-Trp6-LHRH combined with purified FSH in patients with polycystic ovarian disease.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1988;2(4):319-30.
1988: Schally A V
Oncological applications of somatostatin analogues.
Cancer research 1988;48(24 Pt 1):6977-85.
1988: Bajusz S; Csernus V J; Janaky T; Bokser L; Fekete M; Schally A V
New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.
International journal of peptide and protein research 1988;32(6):425-35.
1988: Kadar T; Redding T W; Ben-David M; Schally A V
Decrease in prolactin receptor affinity in the rat mammary tumor model after treatment with analogs of somatostatin and LH-RH.
Materia medica Polona. Polish journal of medicine and pharmacy 1988;20(4):219-23.
1988: Bokser L; Schally A V
Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor-(1-29)NH2 and decreases elevated prolactin levels in rats.
Endocrinology 1988;123(4):1735-9.
1988: Mason-Garcia M; Vaccarella M; Horvath J; Redding T W; Groot K; Orsolini P; Schally A V
Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(15):5688-92.
1988: Pour P M; Redding T W; Paz-Bouza J I; Schally A V
Treatment of experimental ovarian carcinoma with monthly injection of the agonist D-Trp-6-LH-RH: a preliminary report.
Cancer letters 1988;41(1):105-10.
1988: Scarborough R; Gulyas J; Schally A V; Reeves J J
Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine.
Journal of animal science 1988;66(6):1386-92.
1988: Cavitte J C; Lahlou N; Mialot J P; Mondain-Monval M; Mialot M; Nahoul K; Morel C; Roger M; Schally A V
Reversible effects of long-term treatment with D-Trp6-LH-RH-microcapsules on pituitary-gonadal axis, spermatogenesis and prostate morphology in adolescent and adult dogs.
Andrologia 1988;20(3):249-63.
1988: Karashima T; Schally A V
Superactive somatostatin analog decreases plasma glucose and glucagon levels in diabetic rats.
Peptides 1988;9(3):561-5.
1988: Keret R; Josefsberg Z; Kinarti H; Silbergeld A; Szoke B; Schally A V; Laron Z
Discrimination between growth hormone (GH) deficiency of hypothalamic or pituitary origin: an aid in selecting patients for GH-releasing hormone (RH) prolonged therapy.
Israel journal of medical sciences 1988;24(4-5):207-11.
1988: Parmar H; Rustin G; Lightman S L; Phillips R H; Hanham I W; Schally A V
Response to D-Trp-6-luteinising hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer.
British medical journal (Clinical research ed.) 1988;296(6631):1229.
1988: Karashima T; Zalatnai A; Schally A V
Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(7):2329-33.
1988: Mathé G; Busuttil M; Reynes M; Hagipantelli R; Mauvernay Y; Schally A V
Triptorelin in treatment of cervical and vaginal dysplasia related to papillomavirus.
Lancet 1988;1(8589):819-20.
1988: Bajusz S; Kovacs M; Gazdag M; Bokser L; Karashima T; Csernus V J; Janaky T; Guoth J; Schally A V
Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(5):1637-41.
1988: Kadar T; Redding T W; Ben-David M; Schally A V
Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(3):890-4.
1988: Konturek S J; Bilski J; Jaworek J; Tasler J; Schally A V
Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1988;187(2):241-9.
1988: Grings E E; Scarborough R; Schally A V; Reeves J J
Response to a growth hormone-releasing hormone analog in heifers treated with recombinant growth hormone.
Domestic animal endocrinology 1988;5(1):47-53.
1988: Guoth J G; Sohar I; Zarandi M; Janaky T; Schally A V
Method for isolation of MMP-7-ase isoenzymes from rat muscle tissue extract.
Preparative biochemistry 1988;18(3):361-74.
1988: Ben-David M; Wittliff J L; Fekete M; Kadar T; Biran S; Schally A V
Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1988;42(5):327-34.
1988: Ben-David M; Kadar T; Wittliff J; Biran S; Schally A
Characterization of prolactin receptors and their distribution among American and Israeli women with breast cancer: implications for prediction of hormonal dependency and treatment.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1988;42(2):101-9.
1988: Mathé G; Schally A V; Comaru-Schally A M; Mauvernay R Y; Vovan M L; Machover D; Misset J L; Court B; Bouchard P; Duchier J
Monitoring and treatment of minimal residual cancer of the prostate.
Supplement ... to the journal Medical oncology and tumor pharmacotherapy 1988;1():65-74.
1988: Parmar H; Phillips R H; Rustin G; Lightman S L; Schally A V
Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1988;42(8):531-8.
1988: Telegdy G; Vécsei L; Schally A V
The effects of different receptor blockers on the H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH induced inhibition of extinction of active avoidance behaviour.
Acta physiologica Hungarica 1988;72(3-4):315-20.
1988: Redding T W; Schally A V
Use of analogs of LH-RH and somatostatin for the treatment of hormone dependent cancers.
Progress in clinical and biological research 1988;262():217-40.
1988: Zalatnai A; Paz-Bouza J I; Redding T W; Schally A V
Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
The Prostate 1988;12(1):85-98.
1988: Kovacs M; Gulyas J; Bajusz S; Schally A V
An evaluation of intravenous, subcutaneous, and in vitro activity of new agmatine analogs of growth hormone-releasing hormone hGH-RH (1-29)NH2.
Life sciences 1988;42(1):27-35.
1988: Kadar T; Ben-David M; Pontes J E; Fekete M; Schally A V
Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer.
The Prostate 1988;12(4):299-307.
1987: Lahlou N; Roger M; Chaussain J L; Feinstein M C; Sultan C; Toublanc J E; Schally A V; Scholler R
Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty.
The Journal of clinical endocrinology and metabolism 1987;65(5):946-53.
1987: González-Bárcena D; Pérez-Sánchez P; Hernández-Meza A R; Rangel-García N; Graef-Sánchez A; Comaru-Schally A M; Schally A V
Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
Archivos de investigación médica 1987;18(4):273-8.
1987: Schally A V; Redding T W
Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(20):7275-9.
1987: Casanueva F F; Villanueva L; Dieguez C; Diaz Y; Cabranes J A; Szoke B; Scanlon M F; Schally A V; Fernandez-Cruz A
Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary.
The Journal of clinical endocrinology and metabolism 1987;65(4):634-42.
1987: Perl V; Marquez J; Schally A V; Comaru-Schally A M; Leal G; Zacharias S; Gomez-Lira C
Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone.
Fertility and sterility 1987;48(3):383-9.
1987: Pawlikowski M; Zelazowski P; Stepien H; Schally A V
Somatostatin and its analog enhance the formation of human leukocyte migration inhibiting factor: further evidence for immunomodulatory action of somatostatin.
Peptides 1987;8(5):951-2.
1987: Guoth J; Olsen D B; Kovacs M; Schally A V
Synthesis, purification and biological evaluation of porcine corticotropin-releasing factor.
Life sciences 1987;41(8):1003-10.
1987: Rubio M A; Torres-Aleman I; Calle J R; Cabranes J A; Schally A V; Charro A L
D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men.
The Journal of clinical endocrinology and metabolism 1987;65(2):368-9.
1987: Karashima T; Cai R Z; Schally A V
Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release.
Life sciences 1987;41(8):1011-9.
1987: Cortes-Prieto J; Lledo A; Avila C; Cortes-Garcia L; D'Acunto A; Luisi M; Comaru-Schally A M; Schally A V
Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas.
International journal of fertility 1987;32(4):290-7.
1987: Bronstein M D; Knoepfelmacher M; Liberman B; Marino R; Germek O A; Schally A V
Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1987;19(6):271-4.
1987: Karashima T; Olsen D; Schally A V
Effect of long-term administration of an analog of growth hormone-releasing factor on the GH response in rats.
Life sciences 1987;40(25):2437-44.
1987: Karashima T; Schally A V
Inhibitory effects of somatostatin analogs on prolactin secretion in rats pretreated with estrogen or haloperidol.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1987;185(1):69-75.
1987: Cai R Z; Karashima T; Guoth J; Szoke B; Olsen D; Schally A V
Superactive octapeptide somatostatin analogs containing tryptophan at position 1.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(8):2502-6.
1987: Schally A V; Paz-Bouza J I; Schlosser J V; Karashima T; Debeljuk L; Gandle B; Sampson M
Protective effects of analogs of luteinizing hormone-releasing hormone against x-radiation-induced testicular damage in rats.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(3):851-5.
1987: Paz-Bouza J I; Redding T W; Schally A V
Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(4):1112-6.
1987: Schally A V; Comaru-Schally A M
Male contraception involving testosterone supplementation: possible increased risks of prostate cancer?
Lancet 1987;1(8530):448-9.
1987: Schally A V
Treatment of hormone-dependent cancer with analogues of hypothalamic hormones. Experimental and clinical studies.
Annals of the New York Academy of Sciences 1987;496():602-7.
1987: Paz-Bouza J I; Schor N A; Monje E; Redding T W; Schally A V
Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone-releasing hormone agonist and novantrone.
The Prostate 1987;10(4):291-302.
1987: Schally A V; Redding T W; Paz-Bouza J I; Comaru-Schally A M; Mathe G
Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.
Progress in clinical and biological research 1987;243A():173-97.
1987: Pawlikowski M; Stepien H; Kunert-Radek J; Zelazowski P; Schally A V
Immunomodulatory action of somatostatin.
Annals of the New York Academy of Sciences 1987;496():233-9.
1987: Dembinski A; Warzecha Z; Konturek S J; Schally A V
Effect of somatostatin on the growth of gastrointestinal mucosa and pancreas in rats. Role of endogenous gastrin.
Gut 1987;28 Suppl():227-32.
1986: Ben-David M; Kadar T; Schally A V
Micromethod for the determination of free and total prolactin receptors: measurement of receptor levels in normal and malignant mammary and prostate tissues.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(21):8375-9.
1986: Schally A V; Kook A I; Monje E; Redding T W; Paz-Bouza J I
Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(22):8764-8.
1986: Sellers K J; Smith M S; Rojas F J; Asch R H; Schally A V; Bartke A
Effects of a long-acting LHRH agonist preparation on plasma gonadotropin and prolactin levels in castrated male rats and on the release of prolactin from ectopic pituitaries.
Regulatory peptides 1986;15(3):219-28.
1986: Casanueva F F; Villanueva L; Diaz Y; Devesa J; Fernandez-Cruz A; Schally A V
Atropine selectively blocks GHRH-induced GH secretion without altering LH, FSH, TSH, PRL and ACTH/cortisol secretion elicited by their specific hypothalamic releasing factors.
Clinical endocrinology 1986;25(3):319-23.
1986: Zárate A; Fonseca M E; Mason M; Tapia R; Miranda R; Kovacs K; Schally A V
Gonadotropin-secreting pituitary adenoma with concomitant hypersecretion of testosterone and elevated sperm count. Treatment with LRH agonist.
Acta endocrinologica 1986;113(1):29-34.
1986: Debeljuk L; Schally A V
Antifertility effects of a potent LH-RH antagonist in male and female rats.
International journal of fertility 1986;31(4):284-92.
1986: Gonzalez-Barcena D; Rangel-Garcia N E; Perez-Sanchez P L; Gutierrez-Damperio C; Garcia-Carrasco F; Comaru-Schally A M; Schally A V
Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas.
Lancet 1986;2(8499):154.
1986: Patthy M; Schlesinger D H; Horvath J; Mason-Garcia M; Szoke B; Schally A V
Purification and characterization of peptides with corticotropin-releasing factor activity from porcine hypothalami.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(9):2969-73.
1986: Horvath J; Ertl T; Schally A V
Effect of atrial natriuretic peptide on gonadotropin release in superfused rat pituitary cells.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(10):3444-6.
1986: Zorn J R; Tanger C; Roger M; Grenier J; Comaru-Schally A M; Schally A V
Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis.
International journal of fertility 1986;31(1):11-3, 16-27.
1986: Cai R Z; Szoke B; Lu R; Fu D; Redding T W; Schally A V
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(6):1896-900.
1986: Pertzelan A; Keret R; Bauman B; Josefsberg Z; Ben-Zeev Z; Szoke B; Comaru-Schally A M; Schally A V; Laron Z
Responsiveness of pituitary hGH to GRH1-44 in juveniles with obesity.
Acta endocrinologica 1986;111(2):151-3.
1986: Telegdy G; Vécsei L; Bollók I; Schally A V
The effect of beta-(Tyr9)melanotropin-(9-18) on active avoidance behavior, electroconvulsive shock-induced amnesia and T-discrimination learning of rats.
Peptides 1986;7(1):11-3.
1986: Casanueva F F; Villanueva L; Dieguez C; Cabranes J A; Diaz Y; Szoke B; Scanlon M F; Schally A V; Fernandez-Cruz A
Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level.
The Journal of clinical endocrinology and metabolism 1986;62(1):186-91.
1986: Józsa R; Vigh S; Mess B; Schally A V
Ontogenetic development of corticotropin-releasing factor (CRF)-containing neural elements in the brain of the chicken during incubation and after hatching.
Cell and tissue research 1986;244(3):681-5.
1986: Mathé G; Schally A V; Comaru-Schally A M; Mauvernay R Y; Vovan M L; Machover D; Misset J L; Court B; Bouchard P; Duchier J
Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
The Prostate 1986;9(4):327-42.
1986: Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally A M; Schally A V
Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
The Prostate 1986;9(2):207-15.
1986: Roger M; Duchier J; Lahlou N; Schally A V
[Treatment of prostatic cancers by periodic administration of a delayed-release preparation of D-Trp(6)-LHRH]
Annales d'urologie 1986;20(2):109-12.
1985: Patthy M; Horvath J; Mason-Garcia M; Szoke B; Schlesinger D H; Schally A V
Isolation and amino acid sequence of corticotropin-releasing factor from pig hypothalami.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(24):8762-6.
1985: Parmar H; Nicoll J; Stockdale A; Cassoni A; Phillips R H; Lightman S L; Schally A V
Advanced ovarian carcinoma: response to the agonist D-Trp-6-LHRH.
Cancer treatment reports 1985;69(11):1341-2.
1985: Parmar H; Phillips R H; Lightman S L; Edwards L; Allen L; Schally A V
Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma.
Lancet 1985;2(8466):1201-5.
1985: Telegdy G; Vécsei L; Bollók I; Schally A V
The role of the nucleus accumbens septi (NAS) in the behavioral action of beta-(Tyr9)melanotropin-(9-18).
Neuropeptides 1985;6(5):417-24.
1985: Konturek S J; Bilski J; Pawlik W; Thor P; Czarnobilski K; Szoke B; Schally A V
Gastrointestinal secretory, motor and circulatory effects of corticotropin releasing factor (CRF).
Life sciences 1985;37(13):1231-40.
1985: Torres-Alemán I; Debeljuk L; Schally A V
Effects of in vivo pretreatment with D-Trp-6-LH-RH on prolactin and LH secretion by pituitary glands in vitro.
Peptides 1985;6(5):993-5.
1985: Fekete M; Balázs M; Telegdy G; Schally A V
Effects of intracerebroventricular administration of ovine corticotropin-releasing factor (CRF 1-41) on passive avoidance behaviour: lack of influence on monoamine contents of limbic brain areas.
Neuropeptides 1985;6(4):283-292.
1985: Asch R H; Balmaceda J P; Neves de Castro M; Schally A V
Comparison of the subcutaneous and intranasal administration of an LH-RH antagonist ([N-Ac-D-p-Cl-Phe1,2,D-Trp3,D-Arg6,D-Ala10]-LH-RH) in the rhesus monkey.
Advances in contraception : the official journal of the Society for the Advancement of Contraception 1985;1(2):109-17.
1985: Debeljuk L; Torres-Alemán I; Schally A V
D-Trp-6-luteinizing hormone-releasing hormone inhibits hyperprolactinemia in female rats.
Endocrinology 1985;116(6):2227-31.
1985: Vécsei L; Telegdy G; Bollók I; Schally A V
The role of central dopaminergic systems in the behavioral effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH.
Neuropeptides 1985;6(3):183-90.
1985: Debeljuk L; Torres-Aleman I; Schally A V
Effect of an antagonistic analog of LH-RH on haloperidol-induced hyperprolactinemia in female rats.
Peptides 1985;6(3):463-5.
1985: Lewis R W; Dowling K J; Schally A V
D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(9):2975-9.
1985: Pawlikowski M; Stepien H; Kunert-Radek J; Schally A V
Effect of somatostatin on the proliferation of mouse spleen lymphocytes in vitro.
Biochemical and biophysical research communications 1985;129(1):52-5.
1985: Schally A V; Redding T W
Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(8):2498-502.
1985: Asch R H; Rojas F J; Bartke A; Schally A V; Tice T R; Klemcke H G; Siler-Khodr T M; Bray R E; Hogan M P
Prolonged suppression of plasma LH levels in male rats after a single injection of an LH-RH agonist in poly(DL-lactide-co-glycolide) microcapsules.
Journal of andrology 1985;6(2):83-8.
1985: Mason-Garcia M; Vigh S; Comaru-Schally A M; Redding T W; Somogyvari-Vigh A; Horvath J; Schally A V
Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(5):1547-51.
1985: Lengvári I; Liposits Z; Vigh S; Schally A V; Flerkó B
Re-evaluation of "frontal deafferentation" studies on the regulation of ACTH secretion in the light of CRF immunohistology.
Endocrinologia experimentalis 1985;19(1):3-9.
1985: Debeljuk L; Torres-Aleman I; Schally A V
Antiserum to LH-RH blocks haloperidol-induced hyperprolactinemia in female rats.
Neuroendocrinology 1985;40(2):185-7.
1985: Torres-Aleman I; Redding T W; Schally A V
Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(4):1252-6.
1985: Konturek S J; Kwiecien N; Obtulowicz W; Bielanski W; Oleksy J; Schally A V
Effects of somatostatin-14 and somatostatin-28 on plasma hormonal and gastric secretory responses to cephalic and gastrointestinal stimulation in man.
Scandinavian journal of gastroenterology 1985;20(1):31-8.
1985: Hierowski M T; Liebow C; du Sapin K; Schally A V
Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line.
FEBS letters 1985;179(2):252-6.
1985: Konturek S J; Cieszkowski M; Bilski J; Konturek J; Bielanski W; Schally A V
Effects of cyclic hexapeptide analog of somatostatin on pancreatic secretion in dogs.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1985;178(1):68-72.
1985: Vécsei L; Bollók I; Telegdy G; Schally A V
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on different behavioral tests of rats.
Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale 1985;57(3):625-7.
1985: Pertzelan A; Keret R; Bauman B; Ben-Zeev Z; Olsen D B; Szoke B; Comaru-Schally A M; Schally A V; Laron Z
Plasma growth hormone response to synthetic GH-RH1-44 in 52 children and adults with growth hormone deficiency of various etiologies.
Hormone research 1985;22(1-2):24-31.
1985: Kovács M; Lengvári I; Liposits Z; Vigh S; Schally A V; Flerkó B
Corticotropin-releasing factor (CRF)-immunoreactive neurons in the mammillary body of the rat.
Cell and tissue research 1985;240(2):455-60.
1985: Lengvári I; Liposits Z; Vigh S; Schally A V; Flerkó B
The origin and ultrastructural characteristics of corticotropin-releasing factor (CRF)-immunoreactive nerve fibers in the posterior pituitary of the rat.
Cell and tissue research 1985;240(2):467-71.
1985: Redding T W; Schally A V
Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
The Prostate 1985;6(3):219-32.
1985: Hierowski M T; Schally A V
An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
Hormone research 1985;21(2):124-35.
1985: Cehovic G; Redding T W; Schally A V
Changes in the 32P incorporation in rat mammary tumor after chronic administration of LH-RH analogs.
Medical oncology and tumor pharmacotherapy 1985;2(4):243-7.
1985: Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally A M; Schally A V
Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
The Prostate 1985;7(1):21-30.
1985: González-Bárcena D; Mendoza F; Graef A; Medina R; Comaru-Schally A M; Schally A V
Selective inhibitory effect of the analog D5-F-TrP8-D-Cys14 somatostatin on the arginine induced release of insulin, growth hormone and glucagon, in normal human beings.
Archivos de investigación médica 1985;16 Suppl 3():105-14.
1985: Asch R H; Rojas F J; Tice T R; Schally A V
Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle.
International journal of fertility 1985;30(2):19-26.
1984: Steg A; Chiche R; Boccon-Gibod L; Debré B; Duchier J; Schally A V
[Treatment of prostatic cancer with an LH-RH agonist: the D Trp6 LH-RH. Preliminary results in 30 cases]
Annales d'urologie 1984;18(6):388-92.
1984: Lemaigre G; Maral R; Bourut C; Chenu E; Blazsek I; Mauvernay Y; Schally A V; Mathé G
Experimental protection by a luteinizing hormone-releasing hormone agonist of a bone marrow nitrosourea aplasia. Preliminary observations.
Cancer letters 1984;25(2):123-8.
1984: Merchenthaler I; Vigh S; Schally A V; Stumpf W E; Arimura A
Immunocytochemical localization of corticotropin releasing factor (CRF)-like immunoreactivity in the thalamus of the rat.
Brain research 1984;323(1):119-22.
1984: Szilágyi G; Irsy G; Góth M; Szabolcs I; Coy D H; Comaru-Schally A M; Schally A V
Effect of a somatostatin analogue on trophic hormone levels in acromegalic patients with elevated hGH after adenomectomy and treatment with bromocriptine.
Experimental and clinical endocrinology 1984;84(2):190-6.
1984: Merchenthaler I; Hynes M A; Vigh S; Schally A V; Petrusz P
Corticotropin releasing factor (CRF): origin and course of afferent pathways to the median eminence (ME) of the rat hypothalamus.
Neuroendocrinology 1984;39(4):296-306.
1984: Burgos-Briceño L A; Schally A V; Bartke A; Asch R H
Inhibition of serum luteinizing hormone and testosterone with an inhibitory analog of luteinizing hormone-releasing hormone in adult male rhesus monkeys.
The Journal of clinical endocrinology and metabolism 1984;59(4):601-7.
1984: Lahlou N; Duchier J; Feinstein M C; Mauvernay R Y; Roger M; Schally A V
[Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response]
Pathologie-biologie 1984;32(8):906-8.
1984: Redding T W; Schally A V; Tice T R; Meyers W E
Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.
Proceedings of the National Academy of Sciences of the United States of America 1984;81(18):5845-8.
1984: Charro A L; Cabranes J A; Lafuente A; Diaz-Salgado C; Cordero M; Almoguera I; Comaru-Schally A M; Meyers C A; Coy D H; Schally A V
Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly.
Research communications in chemical pathology and pharmacology 1984;45(3):432-44.
1984: Cabranes J A; Vela A; Timoneda F; Meyers C A; Coy D H; Schally A V; Charro A L
Selective inhibition of sleep related growth hormone release by Phe-4-somatostatin.
Research communications in chemical pathology and pharmacology 1984;45(3):421-31.
1984: Comaru-Schally A M; Ramalho A; Leitao P R; Schally A V
Clearance of lung metastases of prostate carcinoma after treatment with LH-RH agonist.
Lancet 1984;2(8397):281-2.
1984: Vécsei L; Bollók I; Telegdy G; Schally A V
Comparative studies with beta-(Tyr9)melanotropin-(9-18) and amphetamine on open-field behavior and striatal dopamine uptake and release.
Pharmacological research communications 1984;16(7):689-97.
1984: Laron Z; Keret R; Bauman B; Pertzelan A; Ben-Zeev Z; Olsen D B; Comaru-Schally A M; Schally A V
Differential diagnosis between hypothalamic and pituitary hGH deficiency with the aid of synthetic GH-RH 1-44.
Clinical endocrinology 1984;21(1):9-12.
1984: Jaworek J; Schally A V; Coy D H; Colaluca J
Effects of analogs of (pyro)Glu-His-Gly-OH on food consumption and gastric acid secretion in rats.
Life sciences 1984;34(26):2597-603.
1984: Mathé G; Schally A V; Vo Van M L; Duchier J; Misset J L; Keiling R
[An analog of gonadoliberin in the treatment of prostatic carcinoma]
Presse médicale (Paris, France : 1983) 1984;13(23):1443-5.
1984: Lytras N; Grossman A; Rees L H; Schally A V; Bloom S R; Besser G M
Corticotrophin releasing factor: effects on circulating gut and pancreatic peptides in man.
Clinical endocrinology 1984;20(6):725-9.
1984: Telegdy G; Vécsei L; Coy D H; Schally A V
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on the in vitro uptake and release of radiolabelled dopamine, noradrenaline and serotonin in rat brain hypothalamic slices.
Neuropeptides 1984;4(3):251-6.
1984: Gero T W; Spatola A F; Torres-Aleman I; Schally A V
Synthesis and biological activity of a cyclic pseudohexapeptide analog of somatostatin.
Biochemical and biophysical research communications 1984;120(3):840-5.
1984: Torres-Aleman I; Mason-Garcia M; Schally A V
Stimulation of insulin secretion by corticotropin-releasing factor (CRF) in anesthetized rats.
Peptides 1984;5(3):541-6.
1984: Merchenthaler I; Vigh S; Schally A V; Petrusz P
Immunocytochemical localization of growth hormone-releasing factor in the rat hypothalamus.
Endocrinology 1984;114(4):1082-5.
1984: Vécsei L; Bollók I; Telegdy G; Coy D H; Schally A V
The effect of beta-(Tyr9)melanotropin-(9-18) on the active avoidance and open-field behavior on rats pretreated with atropine or propranolol.
Pharmacological research communications 1984;16(4):369-79.
1984: McLoughlin L; Tomlin S; Grossman A; Lytras N; Schally A V; Coy D; Besser G M; Rees L H
CRF-41 stimulates the release of beta-lipotrophin and beta-endorphin in normal human subjects.
Neuroendocrinology 1984;38(4):282-4.
1984: Kauli R; Pertzelan A; Ben-Zeev Z; Lewin R P; Kaufman H; Schally A M; Schally A V; Laron Z
Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience.
Clinical endocrinology 1984;20(4):377-87.
1984: Kauli R; Pertzelan A; Ben-Zeev Z; Lewin R P; Kaufman H; Schally A M; Schally A V; Laron Z
Treatment of precocious puberty with LHRH analogue in combination with cyproterone acetate-further experience.
Clinical endocrinology 1984;20(4):377-87.
1984: Schally A V; Comaru-Schally A M; Redding T W
Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1984;175(3):259-81.
1984: Zgliczynski S; Baranowska B; Jeske W; Niewiadomska A; Rozbicka G; Schally A V
The effect of D-Trp6-LRH upon secretion of gonadotrophin--a possible therapeutic application in anorexia nervosa.
Acta endocrinologica 1984;105(2):161-6.
1984: Schally A V; Redding T W; Comaru-Schally A M
Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
Cancer treatment reports 1984;68(1):281-9.
1984: Lytras N; Grossman A; Perry L; Tomlin S; Wass J A; Coy D H; Schally A V; Rees L H; Besser G M
Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary.
Clinical endocrinology 1984;20(1):71-84.
1984: Balmaceda J P; Borghi M R; Burgos L; Pauerstein C J; Schally A V; Asch R H
The effects of chronic administration of LH-RH agonists and antagonists on the menstrual cycle and endometrium of the rhesus monkey.
Contraception 1984;29(1):83-90.
1984: Redding T W; Schally A V
Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
Proceedings of the National Academy of Sciences of the United States of America 1984;81(1):248-52.
1984: Schally A V
Contraceptive potential of analogs of LH-RH.
Network 1984;6(1):7-8.
1984: Petrusz P; Merchenthaler I; Ordronneau P; Maderdrut J L; Vigh S; Schally A V
Corticotropin-releasing factor (CRF)-like immunoreactivity in the gastro-entero-pancreatic endocrine system.
Peptides 1984;5 Suppl 1():71-8.
1984: Józsa R; Vigh S; Schally A V; Mess B
Localization of corticotropin-releasing factor-containing neurons in the brain of the domestic fowl. An immunohistochemical study.
Cell and tissue research 1984;236(1):245-8.
1984: Schally A V; Redding T W; Comaru-Schally A M
Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.
Medical oncology and tumor pharmacotherapy 1984;1(2):109-18.
1984: Hierowski M T; Wettler O; Schally A V
Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1984;38(6):297-303.
1984: Cehovic G; Redding T W; Hierowski M T; Schally A V
Endogenous phosphorylation in Dunning prostate tumors of rats treated with LH-RH analogues.
The Prostate 1984;5(6):605-11.
1984: Vigh S; Schally A V
Interaction between hypothalamic peptides in a superfused pituitary cell system.
Peptides 1984;5 Suppl 1():241-7.
1984: Gonzalez-Barcena D; Mendoza F; Medina R; Coy D H; Murphy W A; Schally A V
Effect of Ala-2-D-Trp-8-D-Cys-14-somatostatin on the arginine induced release of insulin, GH and glucagon in normal men.
Endocrine research 1984;10(1):39-48.
1983: Liposits Z; Lengvári I; Vigh S; Schally A V; Flerkó B
Immunohistological detection of degenerating CRF-immunoreactive nerve fibers in the median eminence after lesion of paraventricular nucleus of the rat. A light and electron microscopic study.
Peptides 1983;4(6):941-53.
1983: Borghi M R; Niesvisky R; Balmaceda J P; Coy D H; Schally A V; Asch R H
Administration of luteinizing hormone-releasing hormone analogs delays ovulation without affecting the luteal function in rhesus monkeys.
Fertility and sterility 1983;40(5):678-82.
1983: Vécsei L; Bollók I; Telegdy G; Coy D H; Schally A V
Effect of intracerebroventricular administration of beta-/Tyr9/-melanotropin-/9-18/ on rotational behavior induced by substantia nigra lesion in rats.
Neuropeptides 1983;3(6):435-42.
1983: Balmaceda J P; Borghi M R; Coy D H; Schally A V; Asch R H
Suppression of postovulatory gonadotropin levels does not affect corpus luteum function in rhesus monkeys.
The Journal of clinical endocrinology and metabolism 1983;57(4):866-8.
1983: Mills T M; Copland J A; Coy D H; Schally A V
Is the postovulatory release of follicle-stimulating hormone in the rabbit mediated by luteinizing hormone-releasing hormone?
Endocrinology 1983;113(3):1020-4.
1983: Soulairac A; Lambinet H; Neuman J C; Schally A V
[Effect of luteoliberin]
Annales médico-psychologiques 1983;141(8):876-82.
1983: Debeljuk L; Maines V M; Coy D H; Schally A V
Effect of a powerful antagonist of LH-RH on testicular function in prepubertal male rats.
Archives of andrology 1983;11(1):89-93.
1983: Asch R H; Balmaceda J P; Borghi M R; Niesvisky R; Coy D H; Schally A V
Suppression of the positive feedback of estradiol benzoate on gonadotropin secretion by an inhibitory analog of luteinizing hormone-releasing hormone (LRH) in oophorectomized rhesus monkeys: evidence for a necessary synergism between LRH and estrogens.
The Journal of clinical endocrinology and metabolism 1983;57(2):367-72.
1983: Marco J; Correas I; Zulueta M A; Vincent E; Coy D H; Comaru-Schally A M; Schally A V; Rodríguez-Arnao M D; Gómez-Pan A
Inhibitory effect of somatostatin-28 on pancreatic polypeptide, glucagon and insulin secretion in normal man.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1983;15(8):363-6.
1983: Schally A V
Current status of antagonistic analogs of LH-RH as a contraceptive method in the female.
Research frontiers in fertility regulation : RFFR / PARFR 1983;2(5):1-16.
1983: Burgos-Briceño L A; Smith C G; Coy D H; Schally A V; Asch R H
Dose response inhibition of the circhoral pulsatile secretion of LH and FSH in rhesus monkeys by the administration of a potent inhibitory analogue of LH-RH ( [N-Ac-D-Trp1, 3, D-p-Cl-Phe2, D-Phe6, D-Ala10]-LH-RH).
Acta Europaea fertilitatis 1983;14(4):255-60.
1983: Balmaceda J P; Coy D H; Schally A V; Asch R H
Temporal changes in FSH and LH concentrations following the administration of a potent LH-RH inhibitory analogue ( [N-Ac-D-Trp1, 3, D-p-Cl-Phe2, D-Phe6, D-Ala10]-LH-RH) to oophorectomized rhesus monkeys.
Acta Europaea fertilitatis 1983;14(4):249-54.
1983: Torres-Aleman I; Vigh S; Merchenthaler I; Somogyvari-Vigh A; Carter W H; Schally A V
Radioimmunoassay of CRF-like material in rat plasma: validation of the method.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1983;173(3):355-61.
1983: Borghi M R; Niesvisky R; Coy D H; Balmaceda J P; Schally A V; Asch R H
Administration of agonistic and antagonistic analogues of LH-RH induce anovulation in Macaca fasicularis.
Contraception 1983;27(6):619-26.
1983: de Quijada M G; Redding T W; Coy D H; Torres-Aleman I; Schally A V
Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(11):3485-8.
1983: Hierowski M T; Altamirano P; Redding T W; Schally A V
The presence of LHRH-like receptors in Dunning R3327H prostate tumors.
FEBS letters 1983;154(1):92-6.
1983: Petrusz P; Merchenthaler I; Maderdrut J L; Vigh S; Schally A V
Corticotropin-releasing factor (CRF)-like immunoreactivity in the vertebrate endocrine pancreas.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(6):1721-5.
1983: Redding T W; Schally A V
Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(5):1459-62.
1983: Merchenthaler I; Vigh S; Petrusz P; Schally A V
The paraventriculo-infundibular corticotropin releasing factor (CRF) pathway as revealed by immunocytochemistry in long-term hypophysectomized or adrenalectomized rats.
Regulatory peptides 1983;5(4):295-305.
1983: Redding T W; Schally A V
Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(4):1078-82.
1983: Telegdy G; Vécsei L; Schally A V; Coy D H
The effects of beta-(Tyr9)melanotropin-(9-18) and H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on the analgesic action of morphine.
Neuropharmacology 1983;22(1):131-4.
1983: Liposits Z; Görcs T; Sétáló G; Lengvári I; Flerkó B; Vigh S; Schally A V
Ultrastructural characteristics of immunolabelled, corticotropin releasing factor (CRF)-synthesizing neurons in the rat brain.
Cell and tissue research 1983;229(1):191-6.
1983: Schally A V; Redding T W; Comaru-Schally A M
Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH.
The Prostate 1983;4(6):545-52.
1982: Vécsei L; Telegdy G; Schally A V; Coy D H
Effects of beta-/Tyr9/melanotropin-/9-18/ on apomorphine-induced stereotyped cage-climbing and on striatal dopamine release in mice. Comparative studies with amphetamine.
Neuropeptides 1982;3(2):91-6.
1982: Merchenthaler I; Vigh S; Petrusz P; Schally A V
Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain.
The American journal of anatomy 1982;165(4):385-96.
1982: Horvath A; Coy D H; Nekola M V; Coy E J; Schally A V; Teplan I
Synthesis and biological activity of LH-RH antagonists modified in position 1.
Peptides 1982;3(6):969-71.
1982: Vigh S; Merchenthaler I; Torres-Aleman I; Sueiras-Diaz J; Coy D H; Carter W H; Petrusz P; Schally A V
Corticotropin releasing factor (CRF): immunocytochemical localization and radioimmunoassay (RIA).
Life sciences 1982;31(22):2441-8.
1982: Redding T W; Schally A V
Inhibition of cell growth by a hypothalamic peptide.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(22):7014-8.
1982: Vécsei L; Telegdy G; Schally A V; Coy D H
Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on passive and active avoidance behavior and on open-field activity of rats.
Pharmacology, biochemistry, and behavior 1982;17(4):633-7.
1982: Nekola M B; Horvath A; Ge L J; Coy D H; Schally A V
Suppression of ovulation in the rat by an orally active antagonist of luteinizing hormone-releasing hormone.
Science (New York, N.Y.) 1982;218(4568):160-2.
1982: Sueiras-Diaz J; Coy D H; Vigh S; Redding T W; Huang W Y; Torres-Aleman I; Schally A V
Synthesis and biological properties of ovine corticotropin-releasing factor (CRF).
Life sciences 1982;31(5):429-35.
1982: Telegdy G; Vécsei L; Schally A V; Coy D H
The interaction between beta-[Tyr9]melanotropin-(9-18), haloperidol and amphetamine in different behavior tests of rats.
Pharmacology, biochemistry, and behavior 1982;17(1):15-8.
1982: Schally A V; Medina-Santillan R; Colaluca J; Carter W H; Redding T W; Jones J; Altamirano-Bustamente P; Coy D H
Inhibition of sham feeding-induced gastric secretion and serum hormonal responses by analogs of (pyro)Glu-His-Gly-OH.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1982;170(3):264-72.
1982: Póvoa L C; Dos Santos R R; Schermann J; Comarú Schally A M; Schally A V
[Prolonged treatment with LH-RH of 6 men with oligoasthenozoospermia and normogonadotropic idiopathic azoospermia]
Reproducción 1982;6(3-4):151-8.
1982: Giguère V; Labrie F; Côté J; Coy D H; Sueiras-Diaz J; Schally A V
Stimulation of cyclic AMP accumulation and corticotropin release by synthetic ovine corticotropin-releasing factor in rat anterior pituitary cells: site of glucocorticoid action.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(11):3466-9.
1982: Labrie F; Veilleux R; Lefevre G; Coy D H; Sueiras-Diaz J; Schally A V
Corticotropin-releasing factor stimulates accumulation of adenosine 3', 5'-monophosphate in rat pituitary corticotrophs.
Science (New York, N.Y.) 1982;216(4549):1007-8.
1982: Konturek S J; Meyers C A; Kwiecien N; Obtulowicz W; Tasler J; Oleksy J; Kopp B; Coy D H; Schally A V
Effect of human pancreatic polypeptide and its C-terminal hexapeptide on pancreatic secretion in man and in the dog.
Scandinavian journal of gastroenterology 1982;17(3):395-9.
1982: Coy D H; Horvath A; Nekola M V; Coy E J; Erchegyi J; Schally A V
Peptide antagonists of LH-RH: large increases in antiovulatory activities produced by basic D-amino acids in the six position.
Endocrinology 1982;110(4):1445-7.
1982: Sundaram K; Connell K G; Bardin C W; Samojlik E; Schally A V
Inhibition of pituitary-testicular function with [D-Trp6] luteinizing hormone-releasing hormone in rhesus monkeys.
Endocrinology 1982;110(4):1308-14.
1982: Schwarzstein L; Aparicio N J; Schally A V
D-Tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia.
International journal of andrology 1982;5(2):171-8.
1982: Grossman A; Kruseman A C; Perry L; Tomlin S; Schally A V; Coy D H; Rees L H; Comaru-Schally A M; Besser G M
New hypothalamic hormone, corticotropin-releasing factor, specifically stimulates the release of adrenocorticotropic hormone and cortisol in man.
Lancet 1982;1(8278):921-2.
1982: Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas A T; Comaru-Schally A M; Schally A V
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(5):1658-62.
1982: Redding T W; Coy D H; Schally A V
Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(4):1273-6.
1982: Paredes Suarez M; Varea Teran J R; Garces G; Avila C; Coy D H; Schally A V
Pituitary response to luteinizing hormone-releasing hormone analog at sea level and high altitudes.
Obstetrics and gynecology 1982;59(1):52-7.
1982: Medina-Santillán R; Comaru-Schally A M; Schally A V
Peptidergic appetite regulation.
Archivos de investigación médica 1982;13(2):117-22 passim.
1981: Asch R H; Eddy C A; Schally A V
Lack of luteolytic effect of D-Trp-6-LH-RH in hypophysectomized rhesus monkeys (Macaca mulatta).
Biology of reproduction 1981;25(5):963-8.
1981: Konturek S J; Jaworek J; Cieszkowski M; Schally A V
Effect of thyrotropin-releasing hormone on gastro-intestinal secretions in dogs.
Life sciences 1981;29(22):2289-98.
1981: Redding T W; Schally A V
Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 1981;78(10):6509-12.
1981: Laron Z; Kauli R; Zeev Z B; Comaru-Schally A M; Schally A V
D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty.
Lancet 1981;2(8253):955-6.
1981: Zarate A; Canales E S; Sthory I; Coy D H; Comaru-Schally A M; Schally A V
Anovulatory effect of a LHRH antagonist in women.
Contraception 1981;24(3):315-20.
1981: Balmaceda J P; Schally A V; Coy D; Asch R H
The effects of an LH-RH antagonist ([N-Ac-D-Trp(1)(3), D-p-Cl-Phe(2), D-Phe(6), D-Ala(10)]-LH-RH) during the preovulatory period of the rhesus monkey.
Contraception 1981;24(3):275-81.
1981: Asch R H; Balmaceda J P; Eddy C A; Siler-Khodr T; Coy D H; Schally A V
Inhibition of the postcastration rise of luteinizing hormone and follicle-stimulating hormone in female rhesus monkeys (Macaca mulatta) by the administration of a luteinizing hormone-releasing hormone inhibitory analog ([N-Ac-D-Trp1-3,D-p-Cl-phe2,D-Phe6,D-Ala10]-LH-RH).
Fertility and sterility 1981;36(3):388-91.
1981: Tolis G; Mehta A; Comaru-Schally A M; Schally A V
Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man.
The Journal of clinical investigation 1981;68(3):819-22.
1981: Schally A V; Chang R C; Arimura A; Redding T W; Fishback J B; Vigh S
High molecular weight peptide with corticotropin-releasing factor activity from porcine hypothalami.
Proceedings of the National Academy of Sciences of the United States of America 1981;78(8):5197-201.
1981: Tolis G; Comaru-Schally A M; Mehta A E; Schally A V
Failure to interrupt established pregnancy in humans by D-tryptophan-6-luteinizing hormone-releasing hormone.
Fertility and sterility 1981;36(2):241-2.
1981: Konturek S J; Tasler J; Cieszkowski M; Jaworek J; Arimura A; Schally A V
Studies on the inhibition of pancreatic secretion by luminal somatostatin.
The American journal of physiology 1981;241(2):G109-15.
1981: Kewley C F; Millar R P; Berman M C; Schally A V
Depolarization- and ionophore-induced release of octacosa somatostatin from stalk median eminence synaptosomes.
Science (New York, N.Y.) 1981;213(4510):913-5.
1981: Walus K M; Pawlik W; Konurek S J; Schally A V
Effect of met-enkephalin and morphine on gastric secretion and blood flow.
Acta physiologica Polonica 1981;32(4):383-92.
1981: Asch R H; Van Sickle M; Rettori V; Balmaceda J P; Eddy C A; Coy D H; Schally A V
Absence of LH-RH binding sites in corpora lutea from rhesus monkeys (Macacca mulatta).
The Journal of clinical endocrinology and metabolism 1981;53(1):215-17.
1981: Hierowski M T; Waring A J; Schally A V
Synthesis and degradation of cyclic nucleotides in the pituitary gland, ovary and testis of rats treated with D-Trp6-luteinizing hormone-releasing hormone.
Biochimica et biophysica acta 1981;675(2):232-8.
1981: Erchegyi J; Coy D H; Nekola M V; Coy E J; Schally A V; Mezo I; Teplan I
Luteinizing hormone-releasing hormone analogs with increased anti-ovulatory activity.
Biochemical and biophysical research communications 1981;100(3):915-20.
1981: Coy D; Jaworek J; Konturek S J; Kwiecien N; Radecki T; Schally A V; Tasler J
Effects of anorexigenic peptide on gastric and pancreatic secretion.
The Journal of physiology 1981;314():225-35.
1981: Levalle O; Tropea L; Aparicio N; Guitelman A; Mancini A; Schally A M; Schally V
D-tryptophan-6-LH-RH-at los doses in the treatment of male subfertility.
Andrologia 1981;13(3):207-11.
1981: Chang R C; Huang W Y; Arimura A; Redding T W; Coy D H; Saffran M; Kong A; Hamilton J W; Cohn D V; Schally A V
Isolation, structure and synthesis of a heptapeptide with in vitro ACTH-releasing activity from porcine hypothalamus.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1981;13(4):228-32.
1981: Nekola M V; Pedroza E; Schally A V
Paradoxical effects of D-Trp6-LHRH in immature female rats correlated with changes in ACTH, prolactin, and corticosterone levels.
Biology of reproduction 1981;24(3):505-11.
1981: Laron Z; Dickerman Z; Ben Zeev Z; Prager-Lewin R; Comaru-Schally A M; Schally A V
Long-term effect of D-Trp6-luteinizing hormone-releasing hormone on testicular size and luteinizing hormone, follicle-stimulating hormone, and testosterone levels in hypothalamic hypogonadotropic males.
Fertility and sterility 1981;35(3):328-31.
1981: Asch R H; Siler-Khodr T M; Smith C G; Schally A V
Luteolytic effect of D-Trp6-luteinizing hormone-releasing hormone in the rhesus monkey (Macaca mulatta).
The Journal of clinical endocrinology and metabolism 1981;52(3):565-71.
1981: Konturek S J; Tasler J; Jaworek J; Pawlik W; Walus K M; Schusdziarra V; Meyers C A; Coy D H; Schally A V
Gastrointestinal secretory, motor, circulatory, and metabolic effects of prosomatostatin.
Proceedings of the National Academy of Sciences of the United States of America 1981;78(3):1967-71.
1981: Ertan A; Taminato T; Akdamar K; Ryan J; Agrawal N M; Schally A V; Arimura A
Immunoreactive somatostatin in human pancreatic secretion.
The Journal of clinical endocrinology and metabolism 1981;52(3):589-91.
1981: Garcia-Centenera J A; Vilchez-Lafuente J M; Hervas F; Alba J P; Pozuelo V; Coy D H; Schally A V
Thyrotrophin and prolactin response to beta-(pyrazolyl-1)-alanine-2-TRH in normal males.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1981;13(2):107-9.
1981: Debeljuk L; Rettori V; Goijman S; Coy D H; Schally A V
Effects of a superactive analogue of LH-RH on the hypothalamo-pituitary-testicular axis in male rats pretreated with estrogens.
Archives of andrology 1981;6(1):39-46.
1981: Rodriguez-Arnao M D; Gomez-Pan A; Rainbow S J; Woodhead S; Comaru-Schally A M; Schally A V; Meyers C A; Coy D H; Hall R
Effects of prosomatostatin on growth hormone and prolactin response to arginine in man. Comparison with somatostatin.
Lancet 1981;1(8216):353-6.
1981: Crim L W; Evans D M; Coy D H; Schally A v
Control of gonadotrophic hormone release in trout: influence of synthetic LH-RH and LH-RH analogues in vivo and in vitro.
Life sciences 1981;28(2):129-35.
1981: Vécsei L; Telegdy G; Schally A V; Coy D H
Effects of beta-(Tyr9)melanotropin-(9-18) decapeptide on passive and active avoidance behavior and on open-field activity of rats.
Peptides 1981;2(4):389-91.
1981: Erchegyi J; Coy D H; Nekola M V; Pedroza E; Coy E J; Mezo I; Schally A V
LH-RH antagonists: further analogs with ring-substituted aromatic residues.
Peptides 1981;2(3):251-3.
1981: Ehrensing R H; Kastin A J; Schally A V
Behavioral and hormonal effects of prolonged high doses of LHRH in male impotency.
Peptides 1981;2 Suppl 1():115-21.
1981: Konturek S J; Tasler J; Jaworek J; Dobrzanska M; Coy D H; Schally A V
Comparison of TRH and anorexigenic peptide on food intake and gastrointestinal secretions.
Peptides 1981;2 Suppl 2():235-40.
1981: Comaru-Schally A M; Schally A V
[Effects of cerebral, hypothalamic and hypophyseal peptides on the central nervous system]
Medicina 1981;41(2):244-56.
1981: Meyers C A; Kastin A J; Schally A V; Coy D H
Use of the mouse vas deferens assay to evaluate the action of somatostatin peptides on gastric acid secretion.
Digestion 1981;21(1):21-4.
1980: Kastin A J; Mauk M D; Schally A V; Coy D H
Unusual dose-related effect of an endorphin analog in a complex maze.
Physiology & behavior 1980;25(6):959-62.
1980: Kastin A J; Coy D H; Schally A V; Zadina J E
Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior.
Pharmacology, biochemistry, and behavior 1980;13(6):913-4.
1980: Debeljuk L; Rettori V; Goijman S; Coy D H; Schally A V
Effect of cycloheximide on the LH release induced by a superactive analog of LH-RH.
Archives of andrology 1980;5(4):345-8.
1980: Kastin A J; Nissen C; Zadina J E; Schally A V; Ehrensing R H
Naloxone-like actions of MIF-1 do not require the presence of the pituitary.
Pharmacology, biochemistry, and behavior 1980;13(6):907-12.
1980: Kastin A J; Kostrzewa R M; Schally A V; Coy D H
Neonatal administration of Met-enkephalin facilitates maze performance of adult rats.
Pharmacology, biochemistry, and behavior 1980;13(6):883-6.
1980: Chang R C; Huang W Y; Redding T W; Arimura A; Coy D H; Schally A V
Isolation and structure of several peptides from porcine hypothalami.
Biochimica et biophysica acta 1980;625(2):266-73.
1980: Meyers C A; Murphy W A; Redding T W; Coy D H; Schally A V
Synthesis and biological actions of prosomatostatin.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(10):6171-4.
1980: Kastin A J; Schally A V; Kostrzewa R M
Possible aminergic mediation of MSH release and of the CNS effects of MSH and MIF-I.
Federation proceedings 1980;39(11):2931-6.
1980: Pedroza E; Vilchez-Martinez J A; Coy D H; Arimura A; Schally A V
Reduction of LH-RH pituitary and estradiol uterine binding sites by a superactive analog of luteinizing hormone-releasing hormone.
Biochemical and biophysical research communications 1980;95(3):1056-62.
1980: Schally A V; Huang W Y; Chang R C; Arimura A; Redding T W; Millar R P; Hunkapiller M W; Hood L E
Isolation and structure of pro-somatostatin: a putative somatostatin precursor from pig hypothalamus.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(8):4489-93.
1980: Lins P E; Efendic S; Meyers C A; Coy D H; Schally A; Luft R
Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo.
Metabolism: clinical and experimental 1980;29(8):728-31.
1980: Vilchez-Martinez J A; Pedroza E; Arimura A; Schally A V
Biphasic fluctuation of pituitary responsiveness to LH-RH during the rat estrous cycle. Role of endogenous LH-RH and ovarian steroids in its modulation.
Neuroendocrinology 1980;31(1):73-80.
1980: Schally A V; Chang R C; Huang W Y; Coy D H; Kastin A J; Redding T W
Isolation, structure, biological characterization, and synthesis of beta-[Tyr9]melanotropin-(9-18) decapeptide from pig hypothalami.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(7):3947-51.
1980: Konturek S J; Thor P; Król R; Dembinski A; Schally A V
Influence of methionine-enkephalin and morphine on myoelectric activity of small bowel.
The American journal of physiology 1980;238(4):G384-9.
1980: Piyachaturawata P; Pedroza E; Huang W Y; Arimura A; Schally A V
Studies on the iodination of LH-RH and the biological and immunological activities of the products.
Life sciences 1980;26(16):1309-18.
1980: Konturek S J; Tasler J; Cieszkowski M; Mikos E; Coy D H; Schally A V
Comparison of methionine-enkephalin and morphine in the stimulation of gastric acid secretion in the dog.
Gastroenterology 1980;78(2):294-300.
1980: Chey W Y; Coy D H; Konturek S J; Schally A V; Tasler J
Enkephalin inhibits the release and action of secretin on pancreatic secretion in the dog.
The Journal of physiology 1980;298():429-36.
1980: Meyers C A; Coy D H; Murphy W A; Redding T W; Arimura A; Schally A V
[Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(1):577-9.
1980: Kastin A J; Zadina J E; Schally A V
Foundations of the clinical use of LHRH: early studies with the porcine hypothalamic hormone.
Materia medica Polona. Polish journal of medicine and pharmacy 1980;12(1-2):33-6.
1980: Schally A V
Aspects of hypothalamic regulation of the pituitary gland. Its implications for the control of reproductive processes.
Materia medica Polona. Polish journal of medicine and pharmacy 1980;12(1-2):9-27.
1980: Schally A V; Meyers C A
Somatostatin, basic and clinical studies. A review.
Materia medica Polona. Polish journal of medicine and pharmacy 1980;12(1-2):28-32.
1980: Schally A V; Arimura A; Coy D H
Recent approaches to fertility control based on derivative of LH-RH.
Vitamins and hormones 1980;38():257-323.
1980: Kastin A J; Arimura A; Gonzalez-Barcena D; Fishback J; Schally A V; Coy D H
Dynamics of injected somatostatin in blood of patients with hepatic failure and acromegaly.
Peptides 1980;1(3):257-9.
1980: Schally A V; Coy D H; Arimura A
LH-RH agonists and antagonists.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 1980;18(5):318-24.
1980: Canales E S; Montvelinsky H; Fonseca M E; Zárate A; Kastin A J; Coy D H; Schally A V
The use of a potent stimulatory LHRH analog (D-Trp-6, LHRH) in the induction of ovulation.
International journal of fertility 1980;25(3):193-7.
1980: Canales E S; Montvelinsky H; Zárate A; Kastin A J; Coy D H; Schally A V
Suppressive effect of an inhibitory LHRH analog on the gonadotropin response to LHRH in normal women.
International journal of fertility 1980;25(3):190-2.
1980: González-Bárcena D; Ortíz H T; Gordon F; Kastin A J; Coy D; Schally A V
Influence of LH-RH agonists and antagonists on gonadotropin release in humans.
International journal of fertility 1980;25(3):185-9.
1980: Arimura A; Talbot S; Serafini P C; Schally A V
Sites of paradoxical action of the LHRH agonist (D-Trp6)-LHRH.
International journal of fertility 1980;25(3):151-6.
1980: Hanker J P; Knippenberg J; Kastin A J; Wickings E J; Schally A V; Coy D H; Schneider H P
Gonadotropin release during repeated administration of d-Leu6 des Gly10-LH-RH-EA at different stages of the menstrual cycle and in functional amenorrhea.
International journal of fertility 1980;25(1):7-17.
1979: Kastin A J; Nissen C; Schally A V; Coy D H
Additional evidence that small amounts of a peptide can cross the blood-brain barrier.
Pharmacology, biochemistry, and behavior 1979;11(6):717-9.
1979: Chihara K; Arimura A; Kubli-Garfias C; Schally A V
Enhancement of immunoreactive somatostatin release into hypophysial portal blood by electrical stimulation of the preoptic area in the rat.
Endocrinology 1979;105(6):1416-8.
1979: Kastin A J; Olson R D; Ehrensing R H; Berzas M C; Schally A V; Coy D H
MIF-I's differential actions as an opiate antagonist.
Pharmacology, biochemistry, and behavior 1979;11(6):721-3.
1979: Kastin A J; Kuzemchak B; Schally A V; Eggert M W
Rat brain melanin at different ages and after various treatments.
Brain research bulletin 1979;4(6):793-7.
1979: Arimura A; Serafini P; Talbot S; Schally A V
Reduction of testicular luteinizing hormone/human chorionic gonadotropin receptors by [D-Trp6]-luteinizing hormone releasing hormone in hypophysectomized rats.
Biochemical and biophysical research communications 1979;90(3):687-93.
1979: Guitelman A; Mancini A M; Aparicio N J; Tropea L; Levalle O; Schally A V
Effect of D-leucine-6-luteinizing hormone-releasing hormone ethylamide in patients with hypogonadotropic hypogonadism with anosmia.
Fertility and sterility 1979;32(3):308-11.
1979: Arimura A; Meyers C A; Case W L; Murphy W A; Schally A V
Suppression of somatostatin levels in the hepatic portal and systemic plasma of the rat by synthetic human pancreatic polypeptide.
Biochemical and biophysical research communications 1979;89(3):913-8.
1979: Kastin A J; Olson R D; Schally A V; Coy D H
CNS effects of peripherally administered brain peptides.
Life sciences 1979;25(5):401-14.
1979: Gomez-Pan A; Scanlon M F; Thorner M O; Rees L H; Schally A V; Hall R; Besser G M
Effect of somatostatin on abnormal growth hormone and prolactin secretion in patients with the carcinoid syndrome.
Clinical endocrinology 1979;10(6):575-81.
1979: Chihara K; Arimura A; Schally A V
Effect of intraventricular injection of dopamine, noreprinephrine, acetylcholine, and 5-hydroxytryptamine on immunoreactive somatostatin release into rat hypophyseal portal blood.
Endocrinology 1979;104(6):1656-62.
1979: Vilchez-Martinez J A; Pedroza E; Arimura A; Schally A V
Paradoxical effects of D-Trp6-luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats.
Fertility and sterility 1979;31(6):677-82.
1979: Hagino N; Nakamoto O; Kunz Y; Arimura A; Coy D H; Schally A V
Effect of D-Trp6-LH-RH on the pituitary-gonadal axis during the luteal phase in the baboon.
Acta endocrinologica 1979;91(2):217-23.
1979: Pinto H; Wajchenberg B L; Lima F B; Goldman J; Comaru-Schally A M; Schally A V
Evaluation of the gonadotrophic responsiveness of the pituitary to acute and prolonged administration of LH/FSH-releasing hormone (LH-RH) in normal females and males.
Acta endocrinologica 1979;91(1):1-13.
1979: Gosselin R E; Fuller G B; Coy D H; Schally A V; Hobson W C
Inhibition of gonadotropin release in chimpanzees by the LH-RH antagonist (D-Phe2, D-Trp3, D-Phe6)-LH-RH.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1979;161(1):21-4.
1979: Chihara K; Arimura A; Schally A V
Immunoreactive somatostatin in rat hypophyseal portal blood: effects of anesthetics.
Endocrinology 1979;104(5):1434-41.
1979: Wass J A; Besser G M; Gomez-Pan A; Scanlon M F; Hall R; Kastin A J; Coy D H; Schally A V
Comparison of long-acting analogues of luteinizing hormone releasing hormone in man.
Clinical endocrinology 1979;10(4):419-30.
1979: Cortés-Prieto J; Arencibia-Rocha J; Aranda A; García-García M D; Coy D H; Schally A V
Attempts to induce ovulation in amenorrheic patients using D-Ala-6-LH-RH propylamide.
International journal of fertility 1979;24(2):108-13.
1978: Wajchenberg B L; Cesar F P; Leme C E; Silva H B; Lerario A C; Coy D H; Schally A V
The effect of serum ionized calcium elevation on somatostatin inhibition of glucose-induced insulin release in humans.
Clinical endocrinology 1978;9(6):515-21.
1978: Coy D H; Hirst B H; Meyers C A; Reed J D; Schally A V
Differentiation of somatostatin receptors involved in inhibition of gastric acid and growth hormone secretion with halogenated Trp8 analogues [proceedings]
The Journal of physiology 1978;285():40P.
1978: Kastin A J; Coy D H; Schally A V; Meyers C A
Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay.
Pharmacology, biochemistry, and behavior 1978;9(5):673-6.
1978: Tcholakian R K; de la Cruz A; Chowdhury A K; Chowdhury M; Schally A V; Steinberger A
Effects of an LH-RH analogue in male rats pretreated with oestradiol benzoate.
Journal of reproduction and fertility 1978;54(2):441-5.
1978: Tcholakian R K; de la Cruz A; Chowdhury M; Steinberger A; Coy D H; Schally A V
Unusual anti-reproductive properties of the analog [d-Leu6,des-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in male rats.
Fertility and sterility 1978;30(5):600-3.
1978: Kastin A J; Nissen C; Schally A V; Coy D H
Radioimmunoassay of DSIP-like material in rat brain.
Brain research bulletin 1978;3(6):691-5.
1978: Chihara K; Arimura A; Chihara M; Schally A V
Studies on the mechanism of growth hormone and thyrotropin responses to somatostatin antiserum in anesthetized rats.
Endocrinology 1978;103(5):1916-23.
1978: Kastin A J; Scollan E L; Ehrensing R H; Schally A V; Coy D H
Enkephalin and other peptides reduce passiveness.
Pharmacology, biochemistry, and behavior 1978;9(4):515-9.
1978: Vilchez-Martinez J A; Pedroza E; Coy D H; Arimura A; Schally A V
Effects of administration of a LH-RH inhibitory analogue on stages of the rat estrous cycle.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1978;159(1):161-4.
1978: Jaramillo C J; Charro-Salgado A L; Pérez-Infante V; Obanza E B; Iglesias F C; Fernández-Cruz A; Coy D H; Schally A V
Clinical studies with d-TRP6-luteinizing hormone-releasing hormone in men with hypogonadotropic hypogonadism.
Fertility and sterility 1978;30(4):430-5.
1978: Schally A V
Aspects of hypothalamic regulation of the pituitary gland.
Science (New York, N.Y.) 1978;202(4363):18-28.
1978: Thor P; Król R; Konturek S J; Coy D H; Schally A V
Effect of somatostatin on myoelectrical activity of small bowel.
The American journal of physiology 1978;235(3):E249-54.
1978: Reed J D; Hirst B H; Gomez-Pan A; Coy D H; Schally A V; Meyers C
Inhibition of gastric acid secretion by stereoisomers of somatostatin.
Metabolism: clinical and experimental 1978;27(9 Suppl 1):1411-3.
1978: Coy D H; Meyers C; Arimura A; Schally A V; Redding T W
Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues.
Metabolism: clinical and experimental 1978;27(9 Suppl 1):1407-10.
1978: Arimura A; Lundqvist G; Rothman J; Chang R; Fernandez-Durango R; Elde R; Coy D H; Schally A V; Meyers C
Radioimmunoassay of somatostatin.
Metabolism: clinical and experimental 1978;27(9 Suppl 1):1139-44.
1978: Seprodi J; Coy D H; Vilchez-Martinez J A; Pedroza E; Huang W Y; Schally A V
Cyclic analogues of luteinizing hormone-releasing hormone with significant biological activities.
Journal of medicinal chemistry 1978;21(9):993-5.
1978: de la Cruz A; Chowdhury M; Tcholakian R K; Coy D H; Schally A V; Steinberger A
Effects of in vivo treatment with an LHRH antagonist analog (D-PHE2-D-PHE6) in the immature male rat.
Biology of reproduction 1978;19(2):364-7.
1978: Kastin A J; Coy D H; Jacquet Y; Schally A V; Plotnikoff N P
CNS effects of somatostatin.
Metabolism: clinical and experimental 1978;27(9 Suppl 1):1247-52.
1978: Chihara K; Arimura A; Chihara M; Schally A V
Effect of intraventricular administration of anti-somatostatin gamma-globulin on the lethal dose-50 of strychnine and pentobarbital in rats.
Endocrinology 1978;103(3):912-6.
1978: Redding T W; Kastin A J; Nikolics K; Schally A V; Coy D H
Disapearance and excretion of labeled alpha-MSH in man.
Pharmacology, biochemistry, and behavior 1978;9(2):207-12.
1978: Vigh S; Sétáló G; Schally A V; Arimura A; Flerkó B
LH-RH-containing nerve fibers in the brain of rats treated with sulpiride or reserpine.
Brain research 1978;152(2):401-5.
1978: Meyers C A; Coy D H; Huang W Y; Schally A V; Redding T W
Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography.
Biochemistry 1978;17(12):2326-31.
1978: Hirst B H; Reed J D; Shaw B; Coy D H; Schally A V
Quantitation of somatostatin inhibition of insulin-stimulated gastric acid and pepsin secretion in the cat.
Acta hepato-gastroenterologica 1978;25(3):208-12.
1978: Konturek S J; Pawlik W; Walus K M; Coy D H; Schally A V
Methionine-enkephalin stimulates gastric secretion and gastric mucosal blood flow.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1978;158(2):156-60.
1978: Schally A V; Huang W Y; Redding T W; Arimura A; Coy D H; Chihara K; Chang R C; Raymond V; Labrie F
Isolation, structural elucidation and synthesis of a tetradecapeptide with in vitro ACTH-releasing activity corresponding to residues 33-46 of the alpha-chain of porcine hemoglobin.
Biochemical and biophysical research communications 1978;82(2):582-8.
1978: Konturek S J; Tasler J; Cieszkowski M; Jaworek J; Coy D H; Schally A V
Inhibition of pancreatic secretion by enkephalin and morphine in dogs.
Gastroenterology 1978;74(5 Pt 1):851-5.
1978: Brown M P; Coy D H; Gomez-Pan A; Hirst B H; Hunter M; Meyers C; Reed J D; Schally A V; Shaw B
Structure-activity relationships of eighteen somatostatin analogues on gastric secretion.
The Journal of physiology 1978;277():1-14.
1978: Jaramillo C J; Charro-Salgado A; Peréz-Infante V; del Campo G L; Botella-Llusiá J; Coy D H; Schally A V
Clinical studies with d-Trp 6-luteinizing hormone-releasing hormone in anovulatory women.
Fertility and sterility 1978;29(4):418-23.
1978: Kastin A J; Coy D H; Schally A V; Miller L H
Peripheral administration of hypothalamic peptides results in CNS changes.
Pharmacological research communications 1978;10(4):293-312.
1978: Vilchez-Martinez J A; Pedroza E; Arimura A; Schally A V
Effects of danazol on gonadotropin secretion after ovariectomy in rats.
Contraception 1978;17(3):283-90.
1978: Schwarzstein L; Aparicio N J; Turner D; De Turner E A; Premoli F; Schally A V
D-leucine-6-luteinizing hormone-releasing hormone ethylamide in the treatment of normogonadotropic oligoasthenospermia.
Fertility and sterility 1978;29(3):332-5.
1978: Seprodi J; Coy D H; Vilchez-Martinez J A; Pedroza E; Schally A V
Branched-chain analogues of luteinizing hormone-releasing hormone.
Journal of medicinal chemistry 1978;21(3):276-80.
1978: Jaramillo C J; Salgado A C; Perez-Infante V; Puente-Cueva M; Botella-Llusia J; Coy D H; Schally A
Levels of luteinizing hormone (LH), follicle-stimulating hormone, and 17 beta-estradiol in response to D-Trp6-LH-releasing hormone during different phases of the menstrual cycle in normal women.
Fertility and sterility 1978;29(2):153-8.
1978: Fernandez-Durango R; Arimura A; Fishback J; Schally A V
Hypothalamic somatostatin and LH-RH after hypophysectomy, in hyper- or hypothyroidism, and during anesthesia in rats.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1978;157(2):235-40.
1978: Schwarzstein L; Aparicio N J; Turner D; de Turner E A; Schally A V; Coy D H
Pituitary and testicular response to LH-RH and to a long-acting analogue (D-leu-6-LH-RH-ethylamide).
Andrologia 1978;10(1):59-65.
1978: Pedroza E; Vilchez-Martinez J A; Arimura A; Schally A V
Danazol effects on gonadotropin basal levels and pituitary responsiveness to LH-RH in immature male rats.
Contraception 1978;17(1):61-9.
1978: Chihara K; Arimura A; Coy D H; Schally A V
Studies on the interaction of endorphins, substance P. and endogenous somatostatin in growth hormone and prolactin release in rats.
Endocrinology 1978;102(1):281-90.
1978: Vigh S; Horváth J; Schally A V; Arimura A; Sétáló G
Simultaneous localization of luteinizing hormone-releasing hormone (LH-RH) and somatostatin-containing nerve fibres in the brain of the rat.
Acta biologica Academiae Scientiarum Hungaricae 1978;29(3):291-4.
1978: Sétáló G; Antalicz M; Saárossy K; Arimura A; Schally A V; Flerkó B
Ontogenesis of the LH-RH-containing neuronal elements in the hypothalamus of the rat.
Acta biologica Academiae Scientiarum Hungaricae 1978;29(3):285-90.
1978: Coy D H; Schally A V
Gonadotrophin releasing hormone analogues.
Annals of clinical research 1978;10(3):139-44.
1978: Sétáló G; Flerkó B; Arimura A; Schally A V
Brain cells as producers of releasing and inhibiting hormones.
International review of cytology. Supplement 1978;(7):1-52.
1978: Cortes-Prieto J; Garcia-Garcia M D; Arencibia-Rocha J; Oriol-Bosch A; Ayuso-Gutiérrez J L; Coy D H; Schally A V
Plasma gonadotropin response to D-Ala6-LH-RH propylamide.
International journal of fertility 1978;23(3):224-8.
1978: Pedroza E; Vilchez-Martinez J A; Coy D H; Arimura A; Schally A V
Correlation between in vivo inhibition of gonadotropin release induced by LH-RH and the blockade of ovulation by synthetic analogues of LH-RH.
International journal of fertility 1978;23(4):294-9.
1978: Schally A V; Coy D H; Meyers C A
Hypothalamic regulatory hormones.
Annual review of biochemistry 1978;47():89-128.
1977: Albinus M; Reed J D; Gomez-Pan A; Schally A V; Coy D H
Comparison of the inhibition of histamine- and pentagastrin-stimulated gastric acid secretion by somatostatin in the cat.
Agents and actions 1977;7(5-6):501-6.
1977: Gordin A; Meyers C; Arimura A; Coy D H; Schally A V
An in vivo model for testing inhibition of arginine-induced insulin and glucagon release by somatostatin analogs.
Acta endocrinologica 1977;86(4):833-41.
1977: Auclair C; Kelly P A; Coy D H; Schally A V; Labrie F
Potent inhibitory activity of [D-Leu6, Des-Gly-NH2(10)]LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat.
Endocrinology 1977;101(6):1890-3.
1977: Schally A V; Kastin A J; Arimura A
Hypothalamic hormones: the link between brain and body.
American scientist 1977;65(6):712-9.
1977: Pedroza E; Vilchez-Martinez J A; Fishback J; Arimura A; Schally A V
Binding capacity of luteinizing hormone-releasing hormone and its analogues for pituitary receptor sites.
Biochemical and biophysical research communications 1977;79(1):234-8.
1977: Gonzalez-Barcena D; Kastin A J; Coy D H; Nikolics K; Schally A V
Suppression of gonadotrophin release in many by an inhibitory analogue of L.H.-releasing hormone.
Lancet 1977;2(8046):997-8.
1977: Guitelman A; Aparicio N J; Mancini A; Encinas M T; Levalle O; Schally A V
Correlation of serum prolactin and LH response to stimulation with LH-RH before and after extirpation of pituitary adenomas with clinical outcome.
The Journal of clinical endocrinology and metabolism 1977;45(4):810-3.
1977: Konturek S J; Tasler J; Krol R; Dembinski A; Coy D H; Schally A V
Effect of somatostatin analogs on gastric and pancreatic secretion.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1977;155(4):519-22.
1977: Cusan L; Dupont A; Kledzik G S; Labrie F; Coy D H; Schally A V
Potent prolactin and growth hormone releasing activity of more analogues of Met-enkephalin.
Nature 1977;268(5620):544-7.
1977: Reeves J J; Tarnavsky G K; Becker S R; Coy D; Schally A V
Uptake of iodinated luteinizing hormone releasing hormone analogs in the pituitary.
Endocrinology 1977;101(2):540-7.
1977: Hagino N; Schally A V
Suppression of luteinization in the baboon by thyrotrophin-releasing hormone (TRH).
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1977;9(4):290-3.
1977: Albinus M; Blair E L; Case R M; Coy D H; Gomez-Pan A; Hirst B H; Reed J D; Schally A V; Shaw B; Smith P A; Smy J R
Comparison of the effect of somatostatin on gastrointestinal function in the conscious and anaesthetized cat and on the isolated cat pancreas.
The Journal of physiology 1977;269(1):77-91.
1977: Phelps C P; Coy D H; Schally A V; Sawyer C H
Blockade of LH release and ovulation in the rabbit with inhibitory analogues of luteinizing hormone releasing hormone.
Endocrinology 1977;100(6):1526-32.
1977: Auclair C; Kelly P A; Labrie F; Coy D H; Schally A V
Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist of human chorionic gonadotropin.
Biochemical and biophysical research communications 1977;76(3):855-62.
1977: Hagino N; Coy D H; Schally A V; Arimura A
Inhibition of release in the baboon by inhibitory analogs of lutheinizing hormone releasing hormone.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1977;9(3):247-8.
1977: Albinus M; Blair E L; Hirst B H; Reed J D; Schally A V; Shaw B
The effects of somatostatin and metiamide on tachyphylaxis of pentagastrin stimulated gastric acid and pepsin secretion in the conscious cat.
The Journal of physiology 1977;266(3):801-17.
1977: Brown G M; Van Loon G R; Hummel B C; Grota L J; Arimura A; Schally A V
Characteristics of antibody produced during chronic treatment with LHRH.
The Journal of clinical endocrinology and metabolism 1977;44(4):784-90.
1977: Schwarzstein L; Aparicio N J; Turner D; de Turner E A; Coy D H; Schally A V
Luteinizing hormone (LH), follicle-stimulating hormone, and testosterone responses to consecutive injections of D-leucine-6-LH-releasing hormone ethylamide in normal men.
Fertility and sterility 1977;28(4):451-5.
1977: Walker J M; Berntson G G; Sandman C A; Coy D H; Schally A V; Kastin A J
An analog of enkephalin having prolonged opiate-like effects in vivo.
Science (New York, N.Y.) 1977;196(4285):85-7.
1977: Schally A V; Redding T W; Arimura A; Dupont A; Linthicum G L
Isolation of gamma-amino butyric acid from pig hypothalami and demonstration of its prolactin release-inhibiting (PIF) activity in vivo and in vitro.
Endocrinology 1977;100(3):681-91.
1977: Vilchez-Martinez J A; Pedroza E; Coy D H; Arimura A; Schally A V
Prolonged release of LH and FSH and depletion of pituitary gonadotropin content after administration of [D-Leu6, desGly-NH2(10)]-LH-RH ethylamide.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1977;154(3):427-30.
1977: Saito M; Kumasaki T; Yaoi Y; Nishi N; Arimura A; Coy D H; Schally A V
Stimulation of luteinizing hormone (LH) and follicle-stimulating hormone by (D-Leu6, des-Gly10-NH2)-LH-releasing hormone ethylamide after subcutaneous, intravaginal, and intrarectal administration to women.
Fertility and sterility 1977;28(3):240-5.
1977: Lind T; Bell S; Gilmore E; Huisjes H J; Schally A V
Insulin disappearance rate in pregnant and non-pregnant women, and in non-pregnant women given GHRIH.
European journal of clinical investigation 1977;7(1):47-52.
1977: Ferland L; Labrie F; Arimura A; Schally A V
Stimulated release of hypothalamic growth hormone-releasing activity by morphine and pentobarbital.
Molecular and cellular endocrinology 1977;6(4-5):247-52.
1977: Meyers C; Arimura A; Gordin A; Fernandez-Durango R; Coy D H; Schally A V; Drouin J; Ferland L; Beaulieu M; Labrie F
Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release.
Biochemical and biophysical research communications 1977;74(2):630-6.
1977: Brownstein M J; Arimura A; Fernandez-Durango R; Schally A V; Palkovits M; Kizer J S
The effect of hypothalamic deafferentation on somatostatin-like activity in the rat brain.
Endocrinology 1977;100(1):246-9.
1977: Nikolics K; Coy D H; Vilchez-Martinez J A; Coy D J; Schally A V
Synthesis and biological activity of position 1 analogs of LH-RH.
International journal of peptide and protein research 1977;9(1):57-62.
1977: Sétáló G; Horváth J; Schally A V; Arimura A; Flerkó B
Effect of the isolated removal of the median eminence (ME) and pituitary stalk (PS) on the immunohistology and hormone release of the anterior pituitary gland grafted into the hypophysiotrophic area (HTA) and/or of the in situ pituitary gland.
Acta biologica Academiae Scientiarum Hungaricae 1977;28(3):333-49.
1977: Arimura A; Pedroza E; Vilchez-Martinez J; Schally A V
Prevention of implantation by [D-Trp6-LH-RH in the rat: comparative study with the effects of large doses of HCG on pregnancy.
Endocrine research communications 1977;4(6):357-66.
1977: Saffran M; Schally A V
The status of the corticotropin releasing factor (CRF).
Neuroendocrinology 1977;24(5-6):359-75.
1977: Schally A V; Coy D H
Stimulatory and inhibitory analogs of luteinizing hormone releasing hormone (LHRH).
Advances in experimental medicine and biology 1977;87():99-121.
1977: Konturek S J; Radecki T; Pucher A; Coy D H; Schally A V
Effect of somatostatin on gastrointestinal secretions and peptic ulcer production in cats.
Scandinavian journal of gastroenterology 1977;12(3):379-83.
1977: Kastin A J; Miller L H; Sandman C A; Schally A V; Plotnikoff N P
CNS and pituitary effects of hypothalamic peptides and MSH.
Essays in neurochemistry and neuropharmacology 1977;1():139-76.
1977: Jaramillo Jaramillo C; Pérez-Infante V; López Maciá A; Salgado A C; Coy D H; Schally A V
Serum LH, FSH and testosterone response to the administration of a new LH-RH analog, D-Trp6-LH-RH, in normal men.
International journal of fertility 1977;22(2):77-84.
1977: Arimura A; Schally A V
Prolactin release inhibiting and stimulating factors in the hypothalamus.
Advances in experimental medicine and biology 1977;87():237-52.
1976: Kastin A J; Scollan E L; King M G; Schally A V; Coy D H
Enkephalin and a potent analog facilitate maze performance after intraperitoneal administration in rats.
Pharmacology, biochemistry, and behavior 1976;5(6):691-5.
1976: Coy D H; Kastin A J; Schally A V; Morin O; Caron N G; Labrie F; Walker J M; Fertel R; Berntson G G; Sandman C A
Synthesis and opioid activities of stereoisomers and other D-amino acid analogs of methionine-enkephalin.
Biochemical and biophysical research communications 1976;73(3):632-8.
1976: Kastin A J; Kuzemchak B; Tompkins R G; Schally A V; Miller M C
Melanin in the rat brain.
Brain research bulletin 1976;1(6):567-72.
1976: Bhathena S J; Perrino P V; Voyles N R; Smith S S; Wilkins S D; Coy D H; Schally A V; Recant L
Reversal of somatostatin inhibition of insulin and glucagon secretion.
Diabetes 1976;25(11):1031-40.
1976: Gordin A; Arimura A; Schally A V
Effect of thyroid hormone excess and deficiency on serum thyrotropin in rats immunized passively with antiserum to somatostatin.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1976;153(2):319-23.
1976: Zárate A; Canales E S; Soria J; Forsbach G; Kastin A J; Schally A V
Therapeutic use of gonadoliberin (follicle-stimulating hormone/luteinizing hormone-releasing hormone) in women.
Fertility and sterility 1976;27(11):1233-9.
1976: Gonzalez-Barcena D; Kastin A J; Schalch D S; Coy D H; Schally A V
Prolonged elevation of luteinizing hormone (LH) after intranasal administration of an analog of LH-releasing hormone.
Fertility and sterility 1976;27(11):1246-9.
1976: Kastin A J; Nissen C; Schally A V; Coy D H
Blood-brain barrier, half-time disappearance, and brain distribution for labeled enkephalin and a potent analog.
Brain research bulletin 1976;1(6):583-9.
1976: Kastin A J; Sandman C A; Miller L H; Schally A V
Some questions related to melanocyte-stimulating hormone.
Mayo Clinic proceedings. Mayo Clinic 1976;51(10):632-6.
1976: Plotnikoff N P; Kastin A J; Coy D H; Christensen C W; Schally A V; Spirtes M A
Neuropharmacological actions of enkephalin after systemic administration.
Life sciences 1976;19(8):1283-8.
1976: Guitelman A; Mancini A; Vargas C; Rozados R; Dujovne A; Lebas C; Aparicio N J; Coy D H; Schally A V
Correlation between leuteinizing hormone responses to luteinizing hormone-releasing hormone (LH-RH) and to D-leu-6-LH-RH-ethylamide in patients with hypothalamo-pituitary disease.
Fertility and sterility 1976;27(10):1154-7.
1976: Nishi N; Coy D H; Coy E J; Arimura A; Schally A V
Suppression of LH-RH-induced ovulation in hamsters and rats by synthetic analogues of LH-RH.
Journal of reproduction and fertility 1976;48(1):119-24.
1976: Coy D H; Labrie F; Savary M; Coy E J; Schally A V
Antagonistic activity of analogs of luteinizing hormone-releasing hormone (LH-RH) in vitro.
Molecular and cellular endocrinology 1976;5(3-4):201-8.
1976: Matsuo H; Baba Y; Nair R M; Arimura A; Schally A V
Classic pages in obstetrics and gynecology. Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence. Biochemical and Biophysical Research Communications, vol. 43, pp. 1334-1339, 1971.
American journal of obstetrics and gynecology 1976;125(8):1141.
1976: Stone S C; Dickey R P; Kastin A J; Schally A V
LHRH and steroid levels in normal ovulatory women.
Obstetrics and gynecology 1976;48(2):146-9.
1976: Schally A V
Some notes on the background of the isolation, determination of structure, synthesis, and early clinical trials of the luteinizing hormone- and follicle-stimulating hormone-releasing hormone.
American journal of obstetrics and gynecology 1976;125(8):1142-7.
1976: Konturek S J; Tasler J; Obtulowicz W; Coy D H; Schally A V
Effect of growth hormone-release inhibiting hormone on hormones stimulating exocrine pancreatic secretion.
The Journal of clinical investigation 1976;58(1):1-6.
1976: Dupont A; Labrie F; Levasseur L; Dussault J H; Schally A V
Effect of thyroxine on the inactivation of thyrotrophin-releasing hormone by rat and human plasma.
Clinical endocrinology 1976;5(4):323-30.
1976: Arimura A; Shino M; de la Cruz K G; Rennels E G; Schally A V
Effect of active and passive immunization with luteinizing hormone-releasing hormone on serum luteinizing hormone and follicle-stimulating hormone levels and the ultrastructure of the pituitary gonadotrophs in castrated male rats.
Endocrinology 1976;99(1):291-303.
1976: Vilchez-Martinez J A; Coy D H; Coy E J; Arimura A; Schally A V
Prolonged anti-luteinizing hormone/follicle-stimulating hormone-releasing activities of some synthetic antagonists of luteinizing hormone-releasing hormone.
Fertility and sterility 1976;27(6):628-35.
1976: Konturek S J; Tasler J; Cieszkowski M; Coy D H; Schally A V
Effect of growth hormone release-inhibiting hormone on gastric secretion, mucosal blood flow, and serum gastrin.
Gastroenterology 1976;70(5 PT.1):737-41.
1976: Aparicio N J; Schwarzstein L; Turner E A; Turner D; Mancini R; Schally A V
Treatment of idiopathic normogonadotropic oligoasthenospermia with synthetic luteinizing hormone-releasing hormone.
Fertility and sterility 1976;27(5):549-55.
1976: Turner D; Turner E A; Aparicio N J; Schwarzstein L; Coy D H; Schally A V
Response of luteinizing hormone and follicle-stimulating hormone to different doses of D-leucine-6-LH-RH ethylamide in oligospermic patients.
Fertility and sterility 1976;27(5):545-8.
1976: Kinder J E; Adams T E; Nett T M; Coy D H; Schally A V; Reeves J J
Serum gonadotropin concentrations and ovarian response in ewes treated with analogs to LH-RH/FSH-RH.
Journal of animal science 1976;42(5):1220-6.
1976: Arimura A; Nishi N; Schally A V
Delayed implantation caused by administration of sheep immunogamma globulin against LHRH in the rat.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1976;152(1):71-5.
1976: Schally A V; Dupont A; Arimura A; Takahara J; Redding T W; Clemens J; Shaar C
Purification of a catecholamine-rich fraction with prolactin release-inhibiting factor (PIF) activity from porcine hypothalami.
Acta endocrinologica 1976;82(1):1-14.
1976: Arimura A; Schally A V
Increase in basal and thyrotropin-releasing hormone (TRH)-stimulated secretion of thyrotropin (TSH) by passive immunization with antiserum to somatostatin in rats.
Endocrinology 1976;98(4):1069-72.
1976: Prasad K U; Roeske R W; Weitl F L; Vilchez-Martinez J A; Schally A V
Structure-activity relationships in luteinizing hormone-releasing hormone.
Journal of medicinal chemistry 1976;19(4):492-5.
1976: Nishi N; Arimura A; de la Cruz K G; Schally A V
Termination of pregnancy by sheep anti-LHRH gamma globulin in rats.
Endocrinology 1976;98(4):1024-30.
1976: Leclerc R; Pelletier G; Puviani R; Arimura A; Schally A V
Immunohistochemical localization of somatostatin in endocrine cells of the rat stomach.
Molecular and cellular endocrinology 1976;4(4):257-61.
1976: Coy D H; Vilchez-Martinez J A; Coy E J; Schally A V
Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6.
Journal of medicinal chemistry 1976;19(3):423-5.
1976: Brownstein M J; Arimura A; Schally A V; Palkovits M; Kizer J S
The effect of surgical isolation of the hypothalamus on its luteinizing hormone-releasing hormone content.
Endocrinology 1976;98(3):662-5.
1976: Schally A V; Dupont A; Arimura A; Redding T W; Nishi N; Linthicum G L; Schlesinger D H
Isolation and structure of somatostatin from porcine hypothalami.
Biochemistry 1976;15(3):509-14.
1976: Arimura A; Smith W D; Schally A V
Blockade of the stress-induced decrease in blood GH by anti-somatostatin serum in rats.
Endocrinology 1976;98(2):540-3.
1976: Sétáló G; Vigh S; Schally A V; Arimura A; Flerkó B
Immunohistological study of the origin of LH-RH-containing nerve fibers of the rat hypothalamus.
Brain research 1976;103(3):597-602.
1976: de la Cruz A; Arimura A; de la Cruz K G; Schally A V
Effect of administration of anti-serum to luteinizing hormone-releasing hormone on gonadal function during the estrous cycle in the hamster.
Endocrinology 1976;98(2):490-7.
1976: Schally A V; Arimura A; Redding T W; Debeljuk L; Carter W; Dupont A; Vilchez-Martinez J A
Re-examination of porcine and bovine hypothalamic fractions for additional luteinizing hormone and follicle stimulating hormone-releasing activities.
Endocrinology 1976;98(2):380-91.
1976: Labrie F; Savary M; Coy D H; Coy E J; Schally A V
Inhibition of luteinizing hormone release by analogs of luteinizing hormone-releasing hormone (LHRH) in vitro.
Endocrinology 1976;98(2):289-94.
1976: Ferland L; Labrie F; Coy D H; Arimura A; Schally A V
Inhibition by six somatostatin analogs of plasma growth hormone levels stimulated by thiamylal and morphine in the rat.
Molecular and cellular endocrinology 1976;4(2):79-88.
1976: Vilchez-Martinez J A; Arimura A; Schally A V
Effect of actinomycin D on the pituitary response to LH-RH.
Acta endocrinologica 1976;81(1):73-81.
1976: Kastin A J; Nissen C; Nikolics K; Medzihradszky K; Coy D H; Teplan I; Schally A V
Distribution of 3H-alpha-MSH in rat brain.
Brain research bulletin 1976;1(1):19-26.
1976: Ferland L; Labrie F; Jobin M; Arimura A; Schally A V
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion.
Biochemical and biophysical research communications 1976;68(1):149-56.
1976: De Athayde Musacchio A V; Cezar Povoa L; Schally A V
[Effect of natural exogenous estrogens on the response to LH-RH (author's transl)]
Reproducci&#